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START (STrAtegies for RelaTives) study: a pragmatic
randomised controlled trial to determine the clinical
effectiveness and cost-effectiveness of a manual-based
coping strategy programme in promoting the mental health
of carers of people with dementia
Gill Livingston,1,2* Julie Barber,3 Penny Rapaport,1,2 Martin Knapp,4,5
Mark Griffin,1 Renee Romeo,5 Derek King,4 Debbie Livingston,1
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1Division of Psychiatry, University College London, London, UK
2Services for Ageing and Mental Health, Camden and Islington NHS Foundation Trust,
London, UK
3Department of Statistical Science and PRIMENT Clinical Trials Unit, University College London,
London, UK
4Personal Social Services Research Unit, London School of Economics and Political Science,
London, UK
5Institute of Psychiatry, King’s College London, London, UK
6Queen Square, University College London Hospitals NHS Foundation Trust, London, UK
7North Essex Partnership University NHS Foundation Trust, Chelmsford, UK
*Corresponding author g.livingston@ucl.ac.uk
Background: Two-thirds of people with dementia live at home, receiving most care from family carers,
about 40% of whom have clinically significant depression or anxiety. This impacts on the person with
dementia, families and society, predicting care breakdown. There are currently no clinically effective and
cost-effective NHS family carer interventions.
Objectives: To assess the STrAtegies for RelaTives (START) intervention in the short (4 and 8 months) and
long term (1 and 2 years) compared with treatment as usual (TAU).
Design: Randomised, parallel-group, superiority trial with blinded assessment recruiting participants
2 : 1 (intervention to TAU) to allow for therapist clustering.
Setting: Three UK mental health services and one neurological service.
Participants: Family carers of people with dementia.
Intervention: Eight-session manual-based coping intervention delivered by supervised psychology
graduates to individuals.
Main outcome measures: Affective symptoms [Hospital Anxiety and Depression Scale-total (HADS-T)]
and cost-effectiveness. Secondary measures: anxiety and depression symptoms and caseness, quality of life
(QoL), abusive behaviour and long-term care home admission.
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Results: Two hundred and sixty participants were randomised (173 intervention, 87 TAU). We used
intention-to-treat analysis in the short term (152 intervention, 77 TAU) and in the long term
(140 intervention, 69 TAU). In the short term, the intervention group had lower HADS-T [mean difference
–1.80, 95% confidence interval (CI) –3.29 to –0.31; p= 0.02] and higher quality-adjusted life-years
(QALYs) (mean difference 0.03, 95% CI –0.01 to 0.08). Costs were no different between groups [mean
£252 (95% CI –£28 to £565) for intervention group]. The cost-effectiveness acceptability curve showed a
greater than 99% chance of being cost-effectiveness at a £30,000/QALY willingness-to-pay threshold and
a high probability of cost-effectiveness based on the HADS-T score. Carers in the intervention group had
less case-level depression [odds ratio (OR) 0.24, 95% CI 0.07 to 0.76], a trend towards reduced case-level
anxiety (OR 0.30, 95% CI 0.08 to 1.05), lower Hospital Anxiety and Depression Scale-anxiety (HADS-A)
(–0.91, 95% CI –1.76 to –0.07; p= 0.03) and Hospital Anxiety and Depression Scale-depression
(HADS-D) (–0.91, 95% CI –1.71 to –0.10; p= 0.03) and higher Health Status Questionnaire (HSQ) QoL
(mean difference 4.09, 95% CI 0.34 to 7.83). Group differences in abusive behaviour (OR 0.48,
95% CI 0.18 to 1.27) and the person with dementia’s quality of life-Alzheimer’s disease (QoL-AD)
(mean increase 0.59, 95% CI –0.72 to 1.89) were not significant. In the long term, the intervention group
had lower HADS-T (mean difference –2.58, 95% CI –4.26 to –0.90; p= 0.03) and higher QALYs (mean
difference 0.03, 95% CI –0.01 to 0.06). Carers in the intervention group had less case-level depression
(OR 0.14, 95% CI 0.04 to 0.53), a trend towards reduced case-level anxiety (OR 0.57, 95% CI 0.26 to
1.24), lower HADS-A (–1.16, 95% CI –2.15 to –0.18) and HADS-D (1.45, 95% CI –2.32 to –0.57), and
higher HSQ (mean difference 7.47, 95% CI 2.87 to 12.08). Thirty-two (18.7%) people with dementia in
the intervention group and 17 (20.2%) in TAU were admitted to a care home (hazard ratio 0.83, 95% CI
0.44 to 1.56; p= 0.56). There were no significant differences between groups in abusive behaviour
(OR 0.83, 95% CI 0.36 to 1.94), the person with dementia’s QoL-AD (0.17, 95% CI –1.37 to 1.70) or
costs (£336, 95% CI –£223 to £895) for intervention group. The probability that the intervention would be
seen as cost-effective at £30,000/QALY threshold and cost-effectiveness on the HADS-T remained high.
Conclusions: The START intervention was clinically effective and cost-effective in the short and longer
term. The results are robust to the sensitivity analyses performed. Future work is needed to consider
mechanism of action; the effects on people with dementia in clinical terms (cognition, neuropsychiatric
symptoms, longer-term care home admission); and on health and social care costs. In addition, we will
explore the effects of carer abusive behaviour on the care recipient’s care home admission and if this then
reduces abusive behaviour. We would also like to implement START and evaluate this implementation in
clinical practice.
Trial registration: Current Controlled Trials ISCTRN70017938.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Plain English summary
The frequency of dementia is rising as people live longer, meaning that there are more people withdementia, two-thirds of whom are cared for at home by their families. About 40% of those family
carers of people with dementia have clinically significant depression or anxiety, often leading to them
becoming unable to care so that the person with dementia has to be looked after in a care home.
Although there have been some interventions which help reduce family carers’ depression and anxiety,
they have neither been designed to be used routinely in the NHS nor had their cost-effectiveness tested.
Our START (STrAtegies for RelaTives) study was a randomised controlled trial of an eight-session manual,
adapted from an American programme called ‘Coping with Caregiving’. It was delivered by psychology
graduates to carers individually. We compared it with usual treatment by using a computer program to
decide randomly whether or not carers should be in the intervention or the control group. We found that
START decreased carers’ anxiety and depression and improved their quality of life (QoL) in the short term
(8 months after the study started) and that it was as effective on these measures in the longer term
(2 years after the study started). The intervention was cost-effective at both times but did not improve the
person with dementia’s QoL. After 2 years, there was a small, but not significant, decrease in the chance
of people with dementia in the intervention group being admitted to a care home.
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Scientific summary
Background
The frequency of dementia is rising. Two-thirds of people with dementia live at home, with family providing
most of their care. About 40% of family carers of people with dementia have clinical depression or anxiety;
others have significant psychological symptoms. This impacts on patients, families and society as carer
psychological morbidity predicts care breakdown and, therefore, institutionalisation, as well as elder abuse.
Systematic reviews report successful interventions to reduce carer depression have been individual rather
than group; required active participation; and offered multicomponent strategies to be tailored to carers’
individual needs. Preliminary evidence suggested that interventions for anxiety might be effective if they
include relaxation techniques and strategies to manage caring demands rather than reducing contact.
There are no manual-based therapies currently available for dementia carers in the NHS and no evidence
regarding whether or not standardised psychological interventions can be realistically, effectively and
economically delivered to family carers within NHS services. The National Institute for Health and Care
Excellence (NICE) recognises that quality dementia care should include psychological therapy for family
carers, but recommends further research regarding cost-effectiveness.
Objectives
To test the STrAtegies for RelaTives (START) study’s clinical effectiveness and cost-effectiveness over the
short term (4 and 8 months) and long term (1 and 2 years) post randomisation. The START intervention is
a manual-based individual therapy for dementia carers, delivered by psychology graduates.
Methods
This is a parallel-group, superiority, randomised controlled trial recruiting participants 2 : 1
to intervention : treatment as usual (TAU) to allow for therapist clustering.
Participants
We included self-identified family carers giving informed consent and providing support at least weekly to
people with dementia, living in their own homes and referred in the previous year.
Settings
We recruited through three mental health trusts and a neurology clinic, encompassing urban, suburban
and rural areas, and ethnic and social diversity.
Intervention
The START manual intervention was based on the US ‘Coping with Caregiving’ intervention.
The eight sessions covered:
1. Learning about dementia, carer stress and understanding behaviours.
2–5. Discussion of behaviours or situations the carer finds difficult, incorporating behavioural management,
identifying and changing unhelpful thoughts, assertive communication, increasing communication,
acceptance, accessing emotional support and positive reframing.
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6. Future planning.
7. Pleasant activities.
8. Maintaining skills learnt.
We predefined adherence clinically, as participating in five or more therapy sessions.
Training
We trained and supervised non-clinically trained psychology graduates to deliver the intervention.
Therapists recorded one randomly selected therapy session per participant. An independent rater used a
checklist to score fidelity from 1, ‘not at all’, to 5, ‘very’ focused.
Treatment as usual
We expected TAU from the several teaching trusts to be based on NICE guidelines, i.e. good ‘TAU’.
Randomisation
We used an online computer-generated randomisation system, stratified by trust using random
permuted blocks.
Blinding
The researchers worked in two teams, each assessing outcomes blinded to randomisation status in some
participants and providing therapy to the remaining participants.
Assessments
We interviewed carers at baseline and after 4, 8, 12 and 24 months. At baseline, we collected
sociodemographic details. We collected clinical status and resource use at every interview.
Instruments
l The Hospital Anxiety and Depression Scale (HADS) comprises two components, the HADS-depression
(HADS-D) and HADS-anxiety (HADS-A), with scores from 0 to 21. The HADS-total score (HADS-T)
ranges from 0 to 42 (higher scores indicating more symptoms). We also dichotomised anxiety and
depression scores into ‘case’ and ‘non-case,’ with a cut-off point of 8 or 9.
l The Zarit Burden Interview is a 22-item questionnaire. Higher scores indicate higher burden
(range 0–88).
l The Neuropsychiatric Inventory (NPI) measures psychopathology in dementia patients and higher scores
indicate worse symptoms (range 0–144).
l The Modified Conflict Tactics Scale (MCTS) measures potentially abusive behaviour by carers towards
care recipients. Ten behaviours, ranging from shouting to slapping, over the previous 3 months are
scored as occurring never (0) to all of the time (4). A score ≥ 2 on any item is classified as abusive.
l The Health Status Questionnaire (HSQ) mental health domain measures health-related quality of life
(QoL). Higher scores indicate better outcome (range 0–100).
l The Client Service Receipt Inventory (CSRI) covers services used.
l Quality of life-Alzheimer’s disease (QoL-AD) is family carer rating of the patient’s QoL. Higher scores
indicate better outcome (range 13–52).
l European Quality of Life-5 Dimensions (EQ-5D) is a health status measure used to generate
quality-adjusted life-years (QALYs).
Primary outcomes (short and long term)
1. HADS-T score.
2. Cost-effectiveness: CSRI and EQ-5D.
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Secondary outcomes (short and long term)
1. Depression and anxiety scores and caseness scores on the HADS.
2. Carer mental health (HSQ score) and care recipient QoL (QoL-AD).
3. MCTS.
4. Cost-effectiveness: CSRI and HADS-T.
Long-term secondary outcome
Time to care home admission.
Sample size
This was calculated to test our main hypothesis: short-term HADS-T score will be significantly lower in the
intervention than in the TAU group.
We originally powered for a primary outcome of HADS-A score to detect (with 90% power, 5% significance)
a 2-point difference in mean score and a 0.5 change in standard deviation (SD) (assumed SD 4). To account
for therapist clustering, we used a design effect of 1.87 for the intervention group, assuming an average of
30 carers per therapist and an intracluster correlation coefficient (ICC) of 0.03. Inflating for 20% attrition, we
planned to recruit 90 for TAU and 168 in the intervention group.
Following recruitment, the research team (with funding body approval) changed the primary outcome to
HADS-T score. We calculated that the available sample size (87 TAU, 173 intervention group) would be
sufficient to detect a 2.4-point difference in HADS-T score (with 80% power, 5% significance). This
calculation assumed a SD for HADS-T score of 7.4 (from pilot data), and allowed for analysis of covariance
(assumed correlation 0.5) and repeated follow-up measurements at 4 and 8 months (correlation 0.7).
We factored attrition in at 10% (based on that observed), and applied a revised design effect of 1.4 for
the intervention arm (ICC of 0.03 and observed average cluster size of 15 carers per therapist).
Statistical methods
Clinical outcomes
We carried out separate analyses to investigate the short- and long-term effects of the intervention.
We used multilevel mixed models to estimate group differences in HADS-T score, taking into account the
partially clustered design, repeated measurements and adjustment for baseline factors. We adjusted for
baseline HADS-T score and centre (each trust was a centre), and for previously reported factors influencing
affective symptoms (carer age, sex, burden and care recipient neuropsychiatric symptoms). Analyses were
carried out on an intention-to-treat basis, but excluded carers for whom data were missing at both 4 and
8 months (short-term follow-up) or long term (12 and 24 months). We took similar approaches for
secondary outcomes. We used parametric shared frailty models for time to 24-month care home admission
and random-effects logistic regression for binary outcomes.
Cost-effectiveness
We examined health and social care costs over periods of 8 months and 2 years post randomisation
alongside QALYs (calculated from EQ-5D by applying societal weights) and HADS-T scores. We analysed
those with complete EQ-5D data at each point, as required to estimate QALYs. We calculated incremental
cost-effectiveness ratios (ICERs) as the difference in the cost of START and TAU divided by the outcome
difference (QALYs/HADS-T score). We plotted confidence intervals (CIs) for cost-effectiveness acceptability
curves (CEACs) and net monetary benefit (NMB) to estimate the impact of uncertainty. We applied a
discount rate of 3.5% to costs and outcome.
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Sensitivity analyses
We used sensitivity analyses to assess our conclusions’ robustness by adjusting for baseline characteristics,
imbalances between randomised groups and differential effects of treatment over time (treatment by time
interaction). We investigated variation of missing outcome by baseline characteristics using logistic
regression, then repeated the main analyses adjusting for factors associated with missingness.
All statistical analyses followed a predefined analysis plan, using Stata version 11 (StataCorp LP,
College Station, TX, USA) for clinical outcomes and Stata version 12 for cost-effectiveness.
Results
We randomised 260 (55%) of 472 carers referred. The others declined participation (n= 181; 38%),
did not meet inclusion criteria (n= 22; 5%) or were uncontactable (n= 9; 2%). Over the 8-month
follow-up period, 12 carers from the control group and 21 from the intervention group withdrew or were
lost to follow-up. The known demographics of those who did or did not consent indicate the study sample
had good external validity. We randomised 173 (67%) participants to the intervention and 87 to TAU.
Randomisation generally achieved good between-group balance of patient and carer demographic and
clinical characteristics.
Intervention
One hundred and thirty (75%) carers in the intervention group attended five or more therapy sessions.
Eight (5%) withdrew before participating in any sessions. Adherence was better in those of white ethnicity
than in other ethnic groups [110 (78%) vs. 19 (61%)], in male carers than in female carers [46 (81%) vs.
84 (72%)] and in those with at least A-level education than in those with a lower level of education
[56 (80%) vs. 74 (72%)]. Adherence did not differ by age [aged < 60 years, 75 (77%) vs. 55 (73%)]
or work situation [paid work 49 (78%) vs. other 81 (74%)].
We scored fidelity rating for 128 out of 166 (77%) intervention participants. The mean score was 4.70
(SD 0.66). Ten therapists (seven female) delivered the intervention to between 11 and 32 carers each.
Short-term outcomes
Clinical
Analysis of HADS-T scores, adjusting for trust and baseline score, showed a significant difference in the
intervention’s favour with an average decrease of –1.46 (95% CI –2.89 to –0.03; p= 0.05). Further
adjustment for factors related to outcome (carer age and sex, NPI and Zarit scores) gave similar results
(mean difference –1.80 points, 95% CI –3.29 to –0.31 points; p= 0.02).
Sensitivity analyses adjusting for missingness predictors gave similar results (mean difference –1.53, 95% CI
–2.96 to –0.10), as did adjusting for baseline imbalances (mean difference –1.78, 95% CI –3.30 to –0.27).
We found HADS-D cases in the intervention group compared with TAU was significantly reduced [adjusted
odds ratio (OR) 0.24, 95% CI 0.07 to 0.76] and some evidence for a reduction in HADS-A caseness
(OR 0.30, 95% CI 0.08 to 1.05).
Adjusted models for the HADS-A and HADS-D scales indicated significant beneficial intervention effects,
with average decreases in scores of –0.91 (95% CI –1.76 to –0.07; p= 0.03) and –0.91 (95% CI –1.71 to
–0.10; p= 0.03), respectively. The carer’s HSQ mental health was significantly higher (mean difference
4.09, 95% CI 0.34 to 7.83). There was no significant difference between groups in the person with
dementia’s QoL-AD (mean increase 0.59, 95% CI –0.72 to 1.89) or in abusive behaviour (OR 0.48,
95% CI 0.18 to 1.27).
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Cost-effectiveness
Carers who received the intervention had non-significantly higher health and social care costs (£252,
95% CI –£28 to £565 with QALY outcome and £247, 95% CI £0 to £569 with HADS-T outcome), after
adjustment for baseline variables. The cost per QALY was £6000. The CEAC showed a > 99% chance of
cost-effectiveness at a willingness-to-pay threshold of £30,000 per QALY gained and a high probability
of cost-effectiveness on the HADS-T.
Sensitivity analyses adjusting for predictors of missingness gave similar results. The mean ICER values
were now £5452 per additional QALY and £107 per 1-point difference in HADS-T score. The intervention
had an approximately 95% likelihood of being seen as cost-effective, rising to 98% at the £30,000
threshold. The second sensitivity analysis results, adjusting for baseline characteristics imbalances, were
again similar. The mean ICER values were £5756 per additional QALY and £112 per 1-point difference in
HADS-T score. At the lower-bound NICE threshold of £20,000, the intervention has a 93% likelihood of
being seen as cost-effective, rising to 98% at the £30,000 threshold. The CIs around NMB for these
sensitivity analyses, taking into account uncertainty in the estimation, suggest that these findings are
robust, although possibly less strong at the £30,000 threshold.
Long-term outcome analysis
Clinical
Long-term mean HADS-T scores were lower in the intervention group than in the TAU group [mean
difference adjusted for trust, baseline score, carer age, sex, NPI and Zarit score –2.58 (95% CI –4.26 to
–0.90)]. If the model did not include factors relating to outcome then the results were similar [–1.84
(95% CI –3.50 to –0.17; p= 0.03)].
Carers in the intervention group were less likely to have case-level depression (adjusted OR 0.14, 95% CI
0.04 to 0.53) and there was a trend towards reduced case-level anxiety (OR 0.57, 95% CI 0.26 to 1.24).
The HADS-A and HADS-D indicated significant beneficial intervention effects, with average score decrease
of –1.16 (95% CI –2.15 to –0.18) and –1.45 (95% CI –2.32 to –0.57), respectively. Intervention carers
had a significantly higher HSQ mental health scale score (mean difference 7.47, 95% CI 2.87 to 12.08).
There was no significant difference between groups in the person with dementia’s QoL (mean QoL-AD
score 0.17, 95% CI –1.37 to 1.70) or in abusive behaviour (OR 0.83, 95% CI 0.36 to 1.94).
There was no interaction of time with outcome.
There was an indication of a decrease risk of admission to 24-hour care in the intervention group.
Seventeen participants (20.2%) in the TAU group and 32 (18.7%) in the intervention group were admitted
to a care home (hazard ratio 0.83, 95% CI 0.44 to 1.56; p= 0.56).
Cost-effectiveness
In the 24-month cost-effectiveness analysis, carers included in this analysis in the intervention group had
non-significantly higher costs [£336 (95% CI –£223 to £895) for QALYs; (n= 144); £303 (95% CI –£206
to £812) for HADS-T (n= 156)], after adjustment for baseline covariates. The cost per QALY was £11,200
and the CEAC showed a 75% chance of cost-effectiveness at a willingness-to-pay threshold of £30,000
per QALY gained. The probability of cost-effectiveness on the HADS-T was 78% at a willingness-to-pay
threshold of £50 per 1-point HADS-T improvement.
In the sensitivity analysis adjusting for missingness predictors, the mean ICER values were £9767 per
additional QALY and £125 per 1-point difference in HADS-T score. The intervention had an approximately
67% likelihood of being seen as cost-effective, rising to 75% at the £30,000 threshold. In the analysis
adjusting for baseline imbalances, the mean ICER values were £8567 per additional QALY, and £209 per
1-point difference in HADS-T score. At the lower NICE threshold of £20,000, the START intervention had a
70% likelihood of being seen as cost-effective, rising to 80% at the £30,000 threshold. The CIs around
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NMB for these two sensitivity analyses taking into account uncertainty in the estimation suggest a degree
of caution should be exercised when considering the finding.
Discussion
The START intervention was clinically effective and cost-effective over 8 months and 2 years. Although
differences were small, they were clinically significant and sustained post intervention, as reflected in QoL
improvements and possibly delayed care home admission. This was a pragmatic trial; participants were
from NHS services and their diverse backgrounds suggest generalisability.
Conclusion
Future quantitative analysis is needed to consider mechanism of action and the effects on people with
dementia in clinical terms (cognition, neuropsychiatric symptoms, longer-term care home admission) and
on health and social care costs. In addition, we will explore the effects of carer abusive behaviour on the
care recipient’s care home admission and if abusive behaviour declines following admission to a care
home. We plan qualitative process investigation of whether or not all of the intervention components were
valued and how it could be improved.
Trial registration
This trial is registered as ISCTRN70017938.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Scientific background
The frequency of dementia will rise dramatically over the next 20 years because of increased longevity.
In the UK, 700,000 people currently have dementia (>1% of the entire UK population), and this figure is
projected to reach over 1 million by 2020 and double again in the 20 years after that.1,2 Dementia affects
the person with the illness, his or her family and society through increasing dependence and challenging
behaviour. In the UK, dementia care is currently estimated to cost £23B per year and costs are projected to
treble in the next 30 years as the number of older people increases;2,3 for comparison, the entire NHS
budget is currently £96B per year. England’s National Dementia Strategy4 emphasises that ‘Family carers
are the most important resource available for people with dementia’ (p. 12). Families and individuals bear
the biggest financial burden; two-thirds of people with dementia live at home, receiving most of their care
from family carers, who save the public purse more than £6B per year.2
About 40% of family carers of people with dementia have clinically significant depression or anxiety, while
others have significant psychological symptoms.5,6 These symptoms are more common when the family carer
is older, a woman, living with the person with dementia and reports greater carer burden and behavioural
symptoms of dementia.5,6 This impacts on the NHS as well as on patients and families, as carer psychological
morbidity, in particular depression, predicts care breakdown and, therefore, institutionalisation,7,8 as well as
elder abuse.9 However, a recent report shows that levels of services and support for people with dementia
and families are inadequate.2 Specialist, individually tailored, psychological support to people with
dementia and their family carers has been shown to reduce the rate of, although not necessarily the time
to, care home admission in the USA, although there is no evidence in the UK.10,11 Only multicomponent
interventions have been shown to be effective in preventing institutionalisation.11,12 Nationally, a reduction in
care home placements would have huge benefits for society, because most older people want to continue
living at home, and those who do live at home report higher quality of life (QoL) than those placed in care
homes.13 There are also economic benefits, for example, in reduced use of health services by carers suffering
from psychological symptoms and, in particular, in reduced use of care homes, which are a very
expensive resource.
Evidence for a coping-based psychological therapy for carers
In our team’s earlier systematic review of interventions to improve the mental health of carers, we
identified, prior to starting this study, 62 references which met our inclusion criteria.10 We found that
behavioural management and coping strategy-based interventions had been efficacious, that interventions
targeting individuals tended to work better than group interventions and that the minimum number of
sessions of individual behaviour management which had been shown to be efficacious was six. Education
about dementia by itself, group behavioural therapy and supportive therapy were not effective carer
interventions. An earlier review had suggested that interventions which required active participation of the
carers were more effective.14 In a further systematic review of evidence about treating dementia carer
anxiety, we found that cognitive–behavioural therapy (CBT) and other therapies developed primarily to
target depression did not effectively treat anxiety.5 Preliminary evidence suggested that an intervention
might be effective if it included relaxation techniques and other strategies to help carers actively find ways
to manage caring demands rather than reducing demands by reducing contact and avoidance. Overall,
while evidence is promising, it is scant and of low quality, and further randomised controlled trials (RCTs)
of interventions for carer psychological health in dementia are required.15
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The Coping with Caregiving programme
The Coping with Caregiving programme16,17 was developed in the USA as a group intervention. It is a
manual-based, psychological intervention delivered in weekly group sessions. It was comprehensibly
evaluated in the Resources for Enhancing Alzheimer’s Caregiver Health project, which recruited carers from
a range of clinical and community sources in the USA; depression scores were significantly decreased in
treatment groups compared with controls in all of the studies16–19 and self-efficacy scores were increased.18
Although the impact of this therapy programme on rates of institutionalisation has not been tested, a
recent systematic review finds that there is some evidence that carer support can reduce institutionalisation
and that therapies such as the Coping with Caregiving programme, which include problem-solving
strategies and offer carers a choice of support strategies which can be tailored to their individual needs,
are most effective.11
Delivery of therapy
The National Institute for Health and Care Excellence (NICE) recognises that psychological therapy for
dementia family carers should be a key component of high-quality dementia care:20 ‘Carers of people with
dementia who experience psychological distress and negative psychological impact should be offered
psychological therapy, including cognitive–behavioural therapy, conducted by a specialist practitioner’
(p. 40). However, the report noted the paucity of evidence in this area, and recommended that research
is needed to address the question: ‘For carers of people with dementia, is a psychological intervention
cost-effective when compared with usual care?’ (p. 45). Our team’s systematic review found only one
study of the cost-effectiveness of a therapeutic approach [similar to the StrAtegies for RelaTives (START)
intervention] for supporting carers.20,21 It examined the cost-effectiveness of a modular, multicomponent
intervention delivered in carers’ homes, in three sessions by telephone, supplemented by five group
sessions (five or six carers in each) delivered by telephone. Focusing on hours of caregiving, the authors
found a significant difference over the 6-month study period, with carers in the intervention group having
more time to dedicate to activities unrelated to caregiving, which has potentially positive impacts on
emotional well-being and QoL.22,23 Therefore, more evidence is needed of the effectiveness and
cost-effectiveness of interventions for supporting caregivers.
Rationale for new therapy in the NHS
Although the efficacy trials discussed above have shown promising reductions in family carer morbidity,
there are no manual-based therapies currently available for dementia carers in the NHS, nor is there an
evidence base to demonstrate whether or not such standardised psychological interventions can be
realistically, effectively and economically delivered to family carers within NHS services. A therapy which
is needed by many NHS consumers that can be effectively implemented only by clinical psychologists
is unlikely to be economically viable. However, too little professional training is unlikely to be helpful;
a recent unstructured, non-manual-based befriending programme delivered by ex-carers was ineffective
in reducing anxiety or depression.24
The UK national agenda is to have a stepped care approach to improve access to psychological therapies
in which less intensive therapy is delivered by psychology graduates supervised by clinical psychologists.25
In this study, we used similar delivery infrastructure; we anticipated that a psychological therapy specifically
tailored to the emotional, practical and information needs of carers could have significant population
benefits, including greater carer and care recipient well-being and decreased statutory care costs.
Our therapy was delivered by psychology graduates, trained and supervised by the coapplicant experts in
psychology, carer involvement, nursing and psychiatry, all of whom work in the NHS. Our intervention was
as suggested by the evidence: individual, manualised, with different elements, required active participation,
incorporated relaxation and was based on the US Coping with Caregiving programme.
INTRODUCTION
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Through our clinical and personal involvement in caring for people with dementia, we are aware that it
can be difficult for carers to attend groups held outside their home at one specific time because of their
caring commitments. There is evidence from systematic reviews that therapies individualised to the carer
receiving them are most effective in delaying institutionalisation,11 and that individual behavioural therapies
are more effective than group interventions in reducing carer morbidity.10 Therefore, with the authors’
agreement, we adapted Coping with Caregiving for NHS use as an individual therapy. As a result, sessions
were quicker to deliver because, in groups, time is needed for all group members’ problems to be
discussed; thus, the number of weekly sessions required decreased from 13 to 8 after piloting.
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Chapter 2 Objectives
We carried out this RCT to test the clinical effectiveness and cost-effectiveness of the manual-basedindividual therapy for dementia carers delivered by psychology graduates compared with treatment
as usual (TAU) in the short (up to 8 months)26,27 and longer term (up to 2 years).
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Chapter 3 Methods
Trial registration
This trial is registered as ISCTRN70017938. The full protocol is available online.
Trial design
The study is a randomised, parallel-group superiority trial, with blinded outcome assessment, recruiting
participants 2 : 1 to intervention and TAU to allow for therapist clustering.
Patient and public involvement
Shirley Nurock, a former family carer working with the Alzheimer’s Society, contributed to the design of
the study at the application stage and commented on the study as part of the Trial Management Group
throughout, including the information sheet. Lynne Ramsey, a family carer, who was then in a Dementias
and Neurodegenerative Disease Research Network (DeNDRoN) group, was a member of the steering group
and helped to make decisions about the study. U Hla Htay, a family carer, who we initially met as a
University College London MSc student, contributed to the Data Monitoring Committee.
Participants
Eligibility criteria for participants
We included family carers of patients with dementia referred in the previous year who:
l provided emotional or practical support at least weekly
l identified themselves as the primary carer of someone with dementia not living in 24-hour care.
We excluded family carers who:
l were unable to give informed consent to the trial
l were currently taking part in a RCT in their capacity as a family carer (not just as an informant)
l lived more than 1.5 hours’ travelling time from the researchers’ base.
To help identify these potential participants, we completed the Mini Mental State Examination28 in carers aged
≥ 60 years. Participants who scored < 24 out of 30 were discussed with the investigators GL or CC to
determine if the low score was related to cognition, mood or education. If carers were judged to have
dementia, they were not included in the study and the referring clinician was informed. This occurred only
once in the study.
Settings and locations where the data were collected
Participants were recruited through three mental health trusts: Camden and Islington NHS Foundation
Trust (CIFT), North Essex Partnership Foundation Trust (NEPFT) and North East London and Essex
Foundation Trust (NELFT) Admiral Nurse Service. We also recruited from a neurology clinic at University
College London (UCL) called the Dementia Research Centre (DRC), a tertiary service whose referrals include
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a high rate of people with young-onset dementia. Although we had planned to recruit from Barnet,
Enfield and Haringey Mental Health Trust, the trust refused to provide extra treatment costs and we did
not recruit from there. The sampling frame encompassed urban, suburban and rural areas and ethnic and
social class diversity. Recruitment was assisted by North Thames DeNDRoN.
Referrals and recruitment procedure
Prospective participants were initially approached by a clinician they knew and given or sent an
information sheet. Those interested in participating were then referred to the research team. The referral
gave the name, sex and relationship of the carer to the patient, as well as the patient’s sex. The
researchers were divided into two teams (A and B). The team that was to carry out blinded assessments
for this client (e.g. A) telephoned the client 24 hours or more after they received the information sheet.
The team member answered any questions and then arranged to meet those who thought they wished to
take part, to obtain their informed consent and complete the baseline assessment before randomisation.
Recruitment of carers to the trial commenced on 4 November 2009 and finished on 8 June 2011. The first
4-month follow-up took place on 4 March 2010, with the final 8-month follow-up on 7 February 2012
and the final 24-month follow-up on 7 June 2013.
Randomisation
The assessing team member gave the details of those enrolled to the trial manager, who entered them
into the online randomisation system. Randomisation to intervention or TAU was carried out using an
online computer-generated randomisation system. Randomisation was stratified by trust using random
permuted blocks. An allocation ratio of 2 : 1 (intervention to TAU) was used to allow for potential
clustering effects by therapist in the intervention arm.29 It was set up and maintained by an independent
Clinical Trials Unit at the Institute of Psychiatry, King’s College London, and accessed only by the START
trial manager and supervising clinical psychologist.
Blinding
Outcome assessors were blinded to randomisation status, but it was not possible to blind study
participants. The researchers worked in two teams, each assessing outcomes for approximately half the
participants and providing therapy to those allocated to treatment in the half of participants they were not
assessing. These teams were in different rooms and had supervision separately so as to remain blinded.
Assessors asked participants at the beginning of each interview not to disclose their allocation group.
The trial manager told the intervention team (B if the assessment team was A or vice versa) the result,
but the assessment team was not informed of the outcome of randomisation. The participant was then
telephoned by a member of the intervention team and informed that they had been allocated either to
TAU and would be contacted for a 4-month follow-up (by the assessment team A, if the therapy team
was A or vice versa) or to the intervention. If allocation was to therapy, an appointment was made for the
first session of the therapy to start. Allocation within the individual team was according to workload.
Intervention
See Appendix 3 for the START manual.
Location of interventions
Participants were usually seen for assessment and for intervention in their own homes, although, if
participants so requested, they were seen in other settings. In the intervention group, most participants
were seen at home, but a minority were seen at UCL (n= 7) or the NHS trust’s offices (n= 13). One carer
was seen both at work and at a local restaurant and another both at home and in the trust.
METHODS
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Development of the intervention manual
Dolores Gallagher-Thompson gave us permission to adapt the ‘Coping with Caregiving’ manual, a
13-session group therapy. We therefore used it to develop the START manual, an eight-session
manual-based individual therapy programme adapted for UK use with individual family carers. The therapy
was adapted by the project team, GL, PR, CC and DL, by considering UK usage of language and culture,
brevity, and the fact that we were addressing individuals rather than a group.
We began by familiarising ourselves with the structure and content of the manual, which made use of the
stress appraisal and coping response model. In this, stress is seen as the mismatch between primary
appraisal (perceived demand) and secondary appraisal (perceived ability to cope and available resources
and options, and principles from CBT).
Why change from group to individual intervention?
Carers face difficulties in attending a group intervention, as it can be impossible to make alternative care
arrangements for their relative and to be available at a prespecified time. Individual therapy also has the
advantage that it can be tailored to the specific problems faced by the carer, and our previous systematic
review found that therapies worked better with individuals rather than groups. Individual therapies are
quicker to deliver, as, in groups, time is needed for all group members’ problems to be discussed and,
so, the number of sessions was decreased.
Reducing the number of sessions
We identified the key components of the intervention and began reducing the 13 sessions to eight shorter
sessions. This was a collaborative process. At this early stage, care was taken to adapt the language and
tone of the American manual to ensure that the language of the revised manual was suitable for its target
audience and to ensure that it was written in a clear and accessible style. Although the content of sessions
varied, each session followed a broadly similar structure: an introduction, a review of a homework task
from the previous session (from session 2 onwards), one or more specific topics including worked examples
and space for carers to identify their own examples, a stress reduction technique, a session summary and a
homework task (e.g. keeping a diary of challenging behaviours for the following week).
In the original manual, the sessions were (1) stress and well-being, (2) target behaviours, (3) strategies for
changing behaviour, (4) refining our behaviour plans, (5) behaviours and thoughts, (6) changing unhelpful
thoughts, (7) communication styles, (8) communication and memory problems, (9) planning for the future,
(10) more planning for the future, (11) pleasant events, (12) refining your pleasant events and (13) review
and conclusion.
Having initially produced the eight-session manual, the team revised each session to ensure that the
content was written in appropriate UK English, was without jargon, was comprehensive and included both
theoretical components and exercises for the participants to work through their own examples and
experiences. Attention was given to ensuring a balance between information provision and interactive
exercises inviting the carer to reflect on their own resources and strategies for coping, as well as relaxation
exercises. In the original manual, ‘planning for the future’ emphasised end-of-life care, but, as most of our
participants were expected to be seen soon after diagnosis, ‘planning for the future’ also encompassed
getting support from other relatives, increasing community services, considering power of attorney and
planning for a care home. The carer could then identify priorities and work through the information which
they felt would be most useful. We piloted the manual by the research assistants trying it with PR, GL, CC,
DL and each other, and altered it whenever it did not flow, or was unclear or repetitive. The research
assistants met in groups, practised delivering the sessions and provided oral and written feedback on how
to improve the sessions and increase the accessibility and clarity of the session content.
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This process was repeated until the researchers and therapists agreed that the sessions were ready for use.
Sessions were practised with each other to ensure that all researchers had the same understanding of how
to deliver the therapy. Two separate versions of the manual were written: one for the carer to keep and
one for the therapist to use, which included additional prompts and guidance to the therapist. In addition
to the text, pictures and images were included to make the manual more user-friendly.
At this point, the sessions were piloted by PR with a carer who would have met the criteria for inclusion in
the study. After each session, the clinical psychologist provided feedback to the team on how both the
process and content was received by the carer, including the ease of delivery and timing of the sessions
and adjustments were made accordingly. Final versions of both the therapist and carer versions of the
manual were then produced for use within the study.
The therapy took place in the carers’ preferred location, usually their home, without the patient in the
room and at a time convenient to them. It was individually tailored to address the particular problems
the carer was experiencing with the person for whom they cared. The therapy was carried out with an
interpreter if the carer did not speak English fluently. Four participants needed translation, three of whom
were randomised to the therapy sessions. The languages were Bengali (two carers), Farsi and Turkish
(one each).
The eight sessions covered:
1. Psychoeducation about dementia, carer stress and understanding behaviours of the person cared for.
This session discussed what dementia was and identified the difficulties faced by the carer. If the carer did
not have any, we had examples of common problems. It introduced the idea of stress and how carers
could recognise when they felt stressed.
2–5. Discussion of behaviours or situations that the carer finds difficult, incorporating behavioural
management techniques including functional analysis; skills to take better care of themselves, including
identifying and changing unhelpful thoughts; assertive communication; effective communication with
people with dementia and promoting emotion-focused coping strategies and acceptance; and where to
get emotional support and positive reframing.
6. Future needs of the patient, with information about care and legal planning specifically adapted to the
UK. We discussed what they wanted to plan and who else they wanted to consult. We gave the carers
information leaflets about making common decisions as individually appropriate.30
7. Planning pleasant activities. This incorporated aspects of behavioural activation and reflected that many
previous pleasant activities were impractical but that there may be many small enjoyable activities which
still could be incorporated and the carer could add them to the day for either themselves or the person
with dementia.
8. Maintaining the skills learned over time. This encompassed discussing which techniques and ideas the
carer had found useful and making a written plan of what they would use in the future.
Each session ended with a different stress reduction technique session. Carers were given homework tasks
to complete between sessions, including relaxation, identifying triggers and reactions to challenging
behaviours, and identifying and challenging negative thoughts. The therapist and the family carer both had
a manual, and carers filled in and kept their own manual. Our group audio-recorded relaxation exercises
for use in these sessions and gave them to carers on a compact disc (CD). The relaxation techniques used
were signal breath, focused breathing, physical grounding, guided imagery (three different versions),
meditation and stretching.
METHODS
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We defined adherence to therapy after consulting with our clinical psychologist supervisor, on clinical
grounds, as participating in five or more sessions.
Training and delivery
We employed and trained psychology graduates with no clinical training to deliver the intervention.
Researchers in the two groups carried out assessments on carers having received training in taking informed
consent, good clinical practice and all the assessment tools being administered. There was a strong practical
focus in the training programme on how to deliver the therapy, potential clinical dilemmas, working with
interpreters, empathic listening skills, effective use of supervision, safe working practice and when to ask for
help. Throughout the training, a strong emphasis was placed upon the researchers guiding carers to where
they themselves could get answers to their concerns or questions rather than feeling the need to provide
specialised advice themselves within the session. We trained therapists to adhere to the manual and required
them to demonstrate, by role-play, competence in delivering each session of the intervention.
Monitoring fidelity to the manualised intervention
Therapists recorded one therapy session per participant. We (PR, CC, DL and GL) devised a fidelity checklist
for each session by considering the most important components of the session. The session to be recorded
was selected at random by the trial manager using a Microsoft Excel (Microsoft Corporation, Redmond,
WA, USA) formula before any interventions were carried out. This session was rated for fidelity to the
manual by a therapist in the same team who was not involved in that participant’s intervention using the
standard checklist. An overall fidelity score for each session was then given by the rater considering whether
or not the therapist was ‘keeping the carer focused on the manual’. Possible scores ranged from 1, meaning
‘not at all’, to 5, meaning ‘very focused’. We planned to have two researchers rate independently initially
while inter-rater reliability was established. Ratings were out of a possible five points. If fidelity scores were
not high, the supervising clinical psychologist addressed this in supervision. This was the case for 7 out of
the 131 recorded sessions, and often it was because carers had refused to participate in a particular aspect
of a session.
Supervision
Following the recruitment and training of the psychology graduates the process of formal clinical
supervision began. Our clinical psychologist, PR, met with each of the two teams (of three or four
psychology assistants) for 1.5 hours of group supervision a fortnight. In addition to this group supervision,
she was available for individual supervision, which either was requested by the psychology graduates on
an ad hoc basis or, on occasion, was initiated by the investigators. Additionally, weekly team meetings
with DL, GL and PR were held for the entire team, during which both procedural and clinical issues were
addressed. The psychology graduates could approach one of the research team at any time if they had
concerns or questions relating to their clients, for example if risk issues arose during a session.
A group supervision format was adopted as it was seen as the most effective use of available resources,
with psychology graduates benefiting from both the professional expertise of their supervisor and the
clinical experiences of their peers. It was hoped that the group format would maximise peer support both
within and outside the supervision sessions and facilitate effective teamworking. The supervision format
was tailored to reflect the specific needs of the START research project. During the course of the project,
supervision performed a number of functions including case management, clinical skills development,
monitoring the fidelity to the manualised intervention and ensuring safe practice with clients and staff
support. Each of these functions is explored in turn below.
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Case management
Once recruitment was under way and psychology graduates were fully trained, they held a caseload of
approximately 4–6 clients for intervention. An important function of supervision was to ensure that all
of these interventions were being managed effectively and appropriately. Therefore, in every group
supervision session, each psychology graduate provided a brief update of his or her caseload, ensuring that
clients and any related issues or concerns did not get overlooked, for example if there was a repeated
pattern of cancellation or non-attendance that the psychology graduate had not identified. This aspect of
supervision was extremely important as the psychology graduates had varied levels of experience and skill
in managing their own caseloads and they were juggling delivering the intervention with offering baseline
and follow-up assessments. This process also encouraged psychology graduates to be transparent about
their work and to recognise when apparently simple or straightforward cases were more complex than
initially perceived. As the cases for intervention were allocated and managed within the team, it was useful
for psychology graduates to be aware of who their colleagues were seeing and who had space to take on
new clients, developing a sense of shared responsibility.
Clinical skills development
Group and individual supervision sessions provided psychology graduates with the opportunity to develop
their clinical skills via a range of approaches. In addition to a brief summary of their caseloads, at the start
of every supervision session the group would agree an agenda and psychology graduates would identify a
clinical challenge or dilemma that they wished to explore in more detail. Generally, each psychology
graduate would talk in detail about one client; however, this very much depended on their present
caseload. If there was a large agenda, psychology graduates were encouraged to prioritise and negotiate
in terms of urgency among themselves. Although the intervention was manualised and psychology
graduates were expected to strictly adhere to the manual, there was great variety in the dilemmas that
they encountered in delivering the intervention. Often, the challenge for the psychology graduates was
how to respond to their clients and overcome difficulties continuing to be empathic while sticking to the
prescribed intervention, for example when carers would repeatedly ask them for solutions or direct advice.
For the more in-depth clinical discussions, PR encouraged the psychology graduates to identify a particular
focus or question which they wanted to address rather than simply talking about a client in an unfocused
way. These clinical discussions encompassed what the psychology graduates thought had worked well and
what they had already tried, as well as what they felt that they could have done differently. In addition to
offering advice and potential solutions to the psychology graduates, she encouraged them to share ideas
and experiences with their peers and to make connections and identify themes across cases so that
supervision was a positive learning experience regardless of whether or not their own cases were being
discussed. As many of the psychology graduates hoped to develop a career in either clinical or academic
psychology, they were keen within supervision sessions to link their practice and experiences to wider
psychological theory. Various themes tended to emerge within their discussions of clinical cases, for
example around grief and loss, or managing the therapeutic relationship, and the group would choose
academic papers and book chapters to read for supervision sessions to extend their learning and
understanding and to connect back to their cases.
In addition to using therapy tapes to monitor the fidelity to the intervention manual, listening to tapes of
sessions provided the opportunity to reflect upon and develop clinical skills. All of the psychology
graduates had the opportunity to play extracts from their taped sessions focusing on both general skills
and the specific challenges that they faced in delivering the intervention to carers, for example how to
manage sessions where the carer was extremely talkative, or how to respond when carers were unable to
identify examples of challenging behaviours or possible coping strategies. Listening to the tapes was often
combined with role-playing sections of intervention sessions to experiment with different ways to deliver
the manual. Although role-play and listening to tapes can be anxiety provoking, because the psychology
METHODS
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graduates were used to listening to and rating each other’s tapes outside supervision, they were more
comfortable using these methods within supervision.
Ensuring safe practice with clients
An important aspect of supervision was to identify and respond to any risks identified during the course of
assessment or intervention. The psychology graduates were provided with specific training in how to
respond to any risks disclosed by carers, in relation to harm to both themselves and the person they were
caring for. Psychology graduates would speak to one of the lead investigators if the abuse Modified
Conflict Tactic Score (MCTS) was in the possibly abusive range (≥ 2) or if they had any concerns about
potential abuse. Similarly, if carers reported high levels of depression or anxiety, this was discussed with
the lead investigators. If concerns were raised, a plan was made with one of the lead investigators about
how to manage the risk and information was shared with the local clinical teams.
Within supervision, psychology graduates were encouraged to identify any concerns about risk and
prioritise these for discussion. As noted above, asking the psychology graduates to talk about their entire
caseload at each session was an important way of ensuring that any concerns were identified. By talking
about examples of good practice as well as difficulties and ensuring that there was an opportunity for
individual supervision on request and a senior member of the team was always available, it was hoped that
a culture of transparency developed and that the psychology graduates would always raise concerns about
their clients. Time was also taken within supervision to highlight the importance of behaving ethically and
safely in all aspects of clinical work, for example reflecting on maintaining clear boundaries clinically
and how to practise safely when working alone in people’s homes.
Staff support
In offering therapeutic interventions to carers of people with dementia, the psychology graduates, who
had limited direct clinical experience, were frequently faced with the often distressing day-to-day lives of
the carers and their relatives with dementia. An important dimension of clinical supervision was to
provide a supportive context for the psychology graduates to develop self-reflexivity, exploring and
making sense of their own responses to the people and situations that they were working with clinically.
The combination of group and individual supervision meant that the psychology graduates benefited from
the support of their peers and felt that their experiences were validated by their shared experiences.
Treatment as usual
As several teaching trusts were involved, we expected the TAU to be similar to good TAU throughout the
UK and based on the NICE guidelines.31 Services are based around the person with dementia. Treatment is
medical, psychological and social. Thus, it consisted of assessment, diagnosis and information, drug
treatment, cognitive stimulation therapy, practical support, treatment of neuropsychiatric and cognitive
symptoms and carer support. We have described TAU by trust below.
Camden and Islington NHS Foundation Trust
Patients and carers in this service were referred by a general practitioner (GP) to the Memory Service for
assessment and diagnosis, assessed at home with family carer and, after investigations, offered a diagnostic
appointment. Medication was prescribed as was appropriate and, if on anti-dementia medication, followed
up by memory clinic nurses. Information and education in dementia was offered initially by nurses but then
by dementia advisors situated in offices in and managed by the Alzheimer’s Society. Patients were offered
cognitive stimulation therapy. Risk assessments were carried out and risk plans put in place, for example
telecare, driving information to the Driver and Vehicle Registry Agency (DVLA), medical identification (ID)
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bracelets, advice regarding power of attorney and capacity assessment, and social services referral for
personal care, day centre and financial advice. Neuropsychiatric symptoms in patients were assessed
and managed.
North East London Foundation Trust
We recruited from NELFT’s Admiral Nurse Service. Admiral Nurses are mental health nurses who specialise
in dementia and work with family carers and people with dementia in the community and other settings.
Family carers are referred to the Admiral Nursing Service through self-referral, directly from the GP, or from
community mental health teams and the Memory Service. They assess the needs of both the carer and the
person with dementia, and provide information, education and advice about caring for someone with
dementia. Admiral Nurses focus on the needs of the family carer and provide emotional and psychological
support to families through the transitional phases of the illness, such as diagnosis, when the condition
advances, care home placement and end-of-life care. Referrals may be made to other services and they
liaise with other health and social care professionals on behalf of the family.
North Essex Partnership University NHS Foundation Trust
Patients and carers in this service were referred by a GP to the Memory Service for assessment and
diagnosis, assessed at home with family carer and, after investigations, offered a diagnostic appointment.
The diagnosis was given in the clinic with a doctor or at home with nurses. Other interventions included
medication as appropriate and, if on antidementia medication, follow-up by memory clinic nurses; risk
assessment with a risk plan put in place, for example telecare and driving information to the DVLA;
medical ID bracelet; and social services referral for personal care or day centre. Information and education
in dementia was offered initially by nurses but thereafter by dementia advisors. Neuropsychiatric symptoms
were assessed and managed. Patients were referred to dementia advisors situated in the Alzheimer’s
Society and carers were offered support groups.
University College London Hospitals NHS Foundation Trust
Patients were referred by their local GP, memory clinic or specialist to this cognitive disorders clinic. They
were assessed in the clinic, with investigations completed during the visit. They were admitted as day case
for cerebrospinal fluid examination or for other investigations. A few weeks later they had a diagnostic
appointment with a neurologist, when they received the results of any tests, and on the same day saw a
nurse consultant for discussion. In this discussion they were given information, education around legal and
financial implications and a risk assessment was carried out. All patients were offered the opportunity to
take part in clinical trials and other research. Available patient support groups were highlighted to them.
This was followed up by telephone consultations. If appropriate, patients returned to the nurse-led
therapeutics clinic for medication. Complex cases were followed up in the clinic and all others signposted
back to their local services.
Barnet, Enfield and Haringey Mental Health Trust
We did not recruit participants from this trust as they did not agree to extra treatment costs.
METHODS
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Chapter 4 Outcomes
Assessments
Carers were interviewed at baseline and 4, 8, 12 and 24 months after randomisation, usually in their own
home, unless they preferred to come to the research team base in UCL. We continued to follow up carers,
asking them to remain in the study for 2 years, even if the person they were looking after went into a care
home or died. They continued to give us data about themselves and their own use of services and, if the
care recipient was in a care home, about the recipient’s use of services. Information collected at baseline
consisted of sociodemographic details about the carer and the person with dementia, and clinical and
resource use items. Collection of clinical and resource use information was repeated at all follow-up data
collection time points.
Sociodemographic details obtained at baseline included age, sex, ethnicity, relationship to the patient
(e.g. spouse or child), level of education, last occupation and living situation.
Other assessments include:
l The Hospital Anxiety and Depression Scale (HADS)32 is a self-complete scale, and is validated for all age
groups and settings, in people who are physically well or ill, and in Asian and African ethnic groups.33
The scale is summarised as HADS-depression (HADS-D) and HADS-anxiety (HADS-A), with scores
ranging from 0 to 21, and as a HADS-total score (HADS-T), with scores ranging from 0 to 42
(higher scores indicating more symptoms). The HADS-T is our chosen primary outcome as it has better
sensitivity and positive predictive value than either of the individual scales in identifying depression
when compared with International Classification of Diseases (ICD) criteria.34 The anxiety and depression
scores were also dichotomised as ‘case’ and ‘non-case’, with a cut-off point of 8 or 9.33
l The Zarit Burden Interview is a 22-item self-report questionnaire and is the most consistently used
measure of carer burden;35 scores range from 0 to 88, with higher scores indicating more burden.
We used it to adjust for the baseline burden on carers as those who have more burden may be
expected to be more stressed.
l The MCTS is a self-completed measure of potentially abusive behaviour by the carers towards those
for whom they care.36 Ten behaviours are scored on whether or not, during the previous 3 months,
these have occurred never (0), almost never (1), sometimes (2), most of the time (3) or all of the time
(4), and these items can be added to make a score. These behaviours range from shouting, through
threatening, to shaking or slapping. A score of 2 or more on any one of the items is classified as an
abusive behaviour. If participants scored this on any item, the score was discussed with a supervising
clinician and, if it was judged that the person with dementia was at risk, permission was asked to
inform the clinical team so that the carer and patient could have appropriate help. This scale has been
validated for use in family carers of people with dementia.37
l The Health Status Questionnaire (HSQ)38 mental health domain measures health-related QoL
throughout the age range, is sensitive to change and has been validated in older and younger people.
It is summarised as a continuous score, ranging from 0 to 100, with higher scores indicating
better outcome.
l European Quality of Life-5 Dimensions (EQ-5D)39,40 is a standardised measure of health status which
provides a simple descriptive profile and a single index value for health status. The EQ-5D descriptive
system comprises five dimensions: mobility, self-care, usual activities, pain or discomfort, and anxiety or
depression. Each dimension has three levels: no problems, some problems and severe problems. The
respondent is asked to indicate his or her health state by ticking (or placing a cross) in the box against
the most appropriate statement in each of the five dimensions. The digits for the five dimensions can
be combined in a five-digit number describing the respondent’s health state.
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l The Client Service Receipt Inventory (CSRI)41 comprehensively covers services, including (but not limited
to) inpatient stays, outpatient attendances, day hospital treatment, visits to social clubs, meals at
lunch clubs, day care visits, and hours spent in contact with community-based professionals such as
community teams for older people, community psychologists, community psychiatrists, GPs, nurses
(either practice, district or community psychiatric), social workers, occupational therapists, paid home
help or care workers, and physiotherapists.
At all time points, carers were also asked for information about the person with dementia using:
l The Neuropsychiatric Inventory (NPI).42 The NPI is a validated instrument with 12 symptom domains that
are scored for their severity and frequency and summarised as a single continuous score (higher scores
indicating worse symptoms). This was included as neuropsychiatric symptoms have been shown to be
associated with carer psychological morbidity. Possible scores range from 0 to 144, with higher scores
indicating more severe symptoms.
l Quality of Life-Alzheimer’s disease (QoL-AD).43 The QoL-AD is an instrument used to rate the QoL of
people with dementia and can be observer rated. It was rated by the family carer to assess the patient’s
overall QoL. The total score ranges from 13 to 52, with higher scores indicating better outcome.
l Clinical Dementia Rating (CDR). The CDR, which we used as an informant instrument, grades the level
of impairment of someone with dementia [categories: healthy (0), very mild (0.5), mild (1), moderate (2),
severe (3)].44
Changes to trial outcome after trial commenced
After the trial commenced, the team began to think further about the clinical relevance of this trial and
concluded that the appropriate clinical questions were ‘does the intervention work?’ and, if it works, ‘does
it keep working and show more effect over time or does the effect wear off?’. As the intervention targets
coping strategies, in theory, over time there may be a larger separation between those who use ‘good’
strategies and those who do not when dealing with the intractable problem of somebody with dementia.
On the other hand, people may revert to their previous tactics and usefulness may be lost over time. In the
last case, we might consider whether or not a ‘top up’ would be appropriate. We therefore proposed to our
steering group, data management group and the National Institute of Health Research Health Technology
Assessment programme that we split the follow-up period into short- and long-term follow-up.
We agreed with all of them that our primary short-term outcome would be repeated measures of the
HADS at 4 and 8 months and our long-term outcome would be repeated measures of the HADS at
1 and 2 years. Our original proposal was inconsistent whether we would use the HADS-A or HADS-D score
as a primary outcome. There are three validation studies in community samples (as opposed to solely, for
example, people with cancer). The largest of these included 6163 participants, more than five times the
sum of the other validation studies and includes random samples of adults throughout the age group and
groups of people with psychiatric and physical illnesses.34 Although the HADS is usually used to generate
scores and caseness for the two subscales of clinically significant anxiety and depression separately, this
study found that HADS-T had better sensitivity and positive predictive value than either of the individual
scales in identifying cases when validated against standardised clinical criteria. The authors comment that
their results are in line with those of previous smaller studies. We therefore concluded that the HADS-T
was the best measure to use.
In addition, we requested and received a 5-year no-cost extension to the trial. We wished to follow up the
participants every 6 months to examine carer mental health and care recipient admission to 24-hour care
settings (homes and continuing care beds) over the longer term or until death at home. This is because
changes in the rate of admissions may become more apparent over a longer time.
OUTCOMES
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We submitted all of these agreed changes as major amendments to National Research Ethics Committee
and appropriate research and development departments and they were agreed.
Short-term primary outcome (up to 8 months’ follow-up)
1. Carer HADS-T score.32,34
2. Cost-effectiveness: costs were measured using the CSRI.40,41 Costs were examined alongside the carer
quality-adjusted life-years (QALYs), calculated from the EQ-5D40,41 by applying societal weights.40,41
Long-term main outcomes (12 to 24 months’ follow-up)
1. Carer HADS-T score.
2. Cost-effectiveness: costs using the CSRI alongside the carer QALYs calculated from the EQ-5D by
applying societal weights.
Seven-year follow-ups
Time to entry to 24-hour care (this was added after funding and is not in this report, which covers the
2 years post recruitment).
Secondary outcomes
Short term (up to 8 months’ follow-up):
1. depression and anxiety caseness and scores on the HADS32
2. carer (HSQ mental health45) and care recipient (QoL-AD43) QoL
3. MCTS score.36,37
Long term (12–24 months’ follow-up):
1. time to entry of the person with dementia to 24-hour care
2. depression and anxiety caseness and scores on the HADS32
3. carer (HSQ mental health45) and care recipient (QoL-AD43) QoL
4. MCTS score.
Sample size
This was calculated to test our main hypotheses that HADS-T score will be significantly lower in the
intervention group than in the TAU group.
This study was originally powered for a primary outcome of HADS-A score based on data from a
cross-sectional pilot study of family carers. Mean HADS-A scores for this group were 7.2 with a standard
deviation (SD) of 4. A decrease of 2 points in mean score and a 0.5 change in SD was considered to be
clinically significant (expert consensus). To detect such a difference, with 90% power at 5% significance
level, 75 participants per group were required. To account for therapist clustering, a design effect of 1.87
was used for the intervention group, assuming an average of 30 carers per therapist and an intracluster
correlation coefficient (ICC) of 0.03.46 Based on these calculations and inflating for 20% attrition, we
planned to recruit 90 participants in the TAU group (no clustering) and 168 participants in the intervention
group (clustering).
DOI: 10.3310/hta18610 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 61
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Livingston et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
17
For the reasons given above, it was agreed that the primary outcome should be changed to HADS-T score.
As recruitment was complete, the sample size available for analysis was fixed with achieved numbers of
87 in the TAU group and 173 in the intervention group. The following power calculation justified that this
achieved sample size was adequate to address the new primary objectives based on the HADS-T outcomes
at 4 and 8 months.
This power calculation considers the short-term primary analysis of HADS-T score using repeated
measurements at 4 and 8 months, with an adjustment (using analysis of covariance) for baseline score.
We calculated that the sample size available (87 carers in the control group and 173 in the intervention
group) would be sufficient to detect a clinically important difference of at least 2.4 points on the HADS-T.
The calculations assumed a HADS-T SD of 7.4 (as given from our cross-sectional pilot study data),
correlation between baseline and follow-up scores of 0.5 and a correlation between repeated follow-up
measurements of 0.7 (both chosen as conservative estimates). Based on these values, with the available
sample size we have 80% power to detect a difference of 2.4 points on the HADS-T and 90% power to
detect a 2.7-point difference, both consistent with differences considered to be clinically important.
This calculation has factored in adjustments for 10% dropout and a design effect of 1.4 for clustering in
the intervention arm (calculated using the known average cluster size, 15 carers per therapist and an
assumed ICC of 0.03).46
Statistical methods
Scoring questionnaires
The relevant outcome scores were calculated from the individual items for each instrument according to
standard algorithms. Where individual items were missing, standard procedures (where available) for the
calculation of these outcome scores were used. Single missing data items on the HADS were imputed
using the subscale mean, but cases with more than one missing item in any given subscale were excluded
as invalid.47 Missing cells on the Brief COPE scale were imputed using the carer’s own mean score for that
particular subscale if there was one item missing (Charles Carver, University of Miami, 2011, personal
communication). For the QoL-AD, if one or two items were missing, the mean of the completed items was
used to impute the missing items. For all other outcomes, scores were calculated only where all relevant
items had been completed.
Clinical outcomes
Separate regression analyses were used to estimate group differences in HADS-T score over the short term
(using 4- and 8-month follow-ups) and the longer term (using 12- and 24-month follow-ups). In both
cases, random-effects models accounted for repeated measurements and therapist clustering in the
intervention arm. Adjustments were made for baseline HADS-T scores and centre (on which randomisation
was stratified), and also on factors believed from the literature to affect affective symptoms (carer age, sex,
carer burden and care recipient neuropsychiatric symptoms). All analyses were carried out by intention to
treat, but we excluded. in the short term. carers who had data missing at both 4- and 8-month follow-up
and, in the longer term, those with data missing at the 12- and 24-month follow-up. If an individual’s
data were available at 4 months but not at 8 months, or vice versa, their partial data were used in the
short-term analysis, and similarly with the 12- and 24-month data for the long-term modelling.
Similar approaches were taken for analyses of the secondary outcomes. Random-effects logistic regression
was used for binary outcomes. In the short term, entry of the person with dementia to 24-hour care
was compared between groups using a simple comparison of proportions (not allowing for clustering)
because of small numbers. For the long-term analyses, the effect of the intervention on the time until
institutionalisation was examined using parametric shared frailty models to allow for clustering in the
intervention arm and adjustment for baseline factors. (The models fitted had a gamma distribution for the
shared frailty and a Weibull survival distribution for time until institutionalisation.)
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Model assumptions were examined by checking the normality of the residuals and also plotting the
residuals compared with the fitted values both at the individual and therapist cluster level. To quantify
therapist clustering, unadjusted ICCs at each follow-up within the intervention group were estimated with
95% confidence intervals (CIs).
Sensitivity analyses were used to reanalyse the outcomes in various ways to assess robustness of our
conclusions. These analyses considered adjustment for imbalances in baseline characteristics between the
randomised groups and the differential effects of treatment over time (treatment by time interaction).
In considering missing data, we examined the extent to which missing outcome varied by baseline
characteristics using logistic regression. In these analyses, for each outcome a binary variable was created
according to whether or not it was missing (1=missing score, 0= valid score). This binary outcome was
used in logistic regression to determine associations with baseline factors. In a sensitivity analysis, the
main analyses for each outcome were repeated adjusting for those factors found to be associated with
missingness, thus making missing at random assumptions more plausible. In the longer-term analyses,
we also fitted models incorporating all repeated measurements (at 4, 8, 12 and 24 months) and examined
the interaction between treatment group and long-/short-term follow-up.
Cost-effectiveness
The primary economic evaluation was a cost-effectiveness analysis comparing differences in treatment
costs for carers receiving the START intervention with QALYs computed from the EQ-5D40 and societal
weights48 over 1–8 months’ and then 1–24 months’ follow-up. In a secondary analysis, differences in
treatment costs were compared with changes in in HADS-T score over the same time periods. Both the
primary and secondary economic evaluations were undertaken from the perspective of health and social
care agencies.
Data on services used and support received by the carer and the person with dementia were collected
using an adapted version of the CSRI as above at baseline (randomisation) and at 4, 8, 12 and 24 months.
On each occasion, the carer was asked to report service use over the previous 4 months. For the primary
economic analyses over 1–8 months and then 1–24 months, our focus was on service use by the carer.
Total carer-related costs were derived by combining health and social care service use data with estimated
unit costs. Costs were calculated for the periods 1–8 months and 1–24 months. We did not collect service
use data during the period between the 12- and 21-month data collection time points (on average
8 months). Costs during this period were interpolated from the 12- and 24-month data.
Unit costs were obtained from publicly available sources and set at 2009–10 prices: Department of Health
National Schedule of Reference Costs 2008–949 for inpatient (accident and emergency) and outpatient
attendances; the Personal Social Services Research Unit (PSSRU) unit cost compendium50 for some inpatient
services such as acute adult inpatient services; most other community-based health and social care
professional services; and voluntary organisation services for a small number of services used by a few
carers. Unit costs of services are listed in Appendix 1.
The cost of the START intervention was calculated using data on time spent by therapists in training
and supervision with a clinical psychologist and contacts that therapists had with carers in delivering the
intervention. Cost per hour of contact for therapists and supervising clinical psychologist were based
on figures in the PSSRU compendium,50 taking the mid-point of the relevant scales and including
employer costs (national insurance and superannuation contributions) and appropriate overheads (capital,
administration and managerial, including recruitment costs). We added costs for the relaxation CDs based
on the market rates for copying and delivering.
We analysed HADS-T and QALY differences between START and TAU interventions using a multilevel,
mixed-effects model to account for therapist clustering in the intervention arm and repeated measures at
4, 8, 12 and 24 months. For the HADS-T analysis, we adjusted for baseline HADS-T score, centre and carer
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age and sex, carer burden (Zarit) and neuropsychiatric symptoms (NPI) of the person with dementia. For
the QALY analyses, we adjusted for the same baseline variables, except substituting QALY for HADS-T.
Differences in total health and social care cost between the START and TAU interventions were regressed
on treatment allocation, baseline costs, centre, carer age and sex, carer burden (Zarit) and care recipient
neuropsychiatric symptoms (NPI). We used a linear multilevel regression model to account for therapist
clustering in the intervention arm and repeated measures for each individual. Non-parametric bootstrapping
was used to estimate 95% CIs for mean costs. Significance (p< 0.05) was judged where the bias-corrected
95% CIs of between-group change score excluded zero.
All analyses were conducted on an intention-to-treat basis; carers were excluded if data were missing at
both 4 and 8 months for the 1–8-month economic analysis, and, for the 1–24-month economic analysis,
carers were excluded if data were missing at 4, 8 and 24 months. Because the estimation of QALYs
requires data at each time point, only complete cases were included in the cost-effectiveness analysis.
No imputation was conducted.
Each incremental cost-effectiveness ratio (ICER) was calculated as the difference in the cost of the START
and TAU interventions divided by the difference in outcome (measured by HADS-T score or QALYs).
Cost-effectiveness acceptability curves (CEACs) were plotted to locate the findings of the economic
evaluation in their wider decision-making context. The CEAC illustrates the probability that the START
intervention would be seen as cost-effective compared with TAU across a range of hypothesised values
placed on incremental outcome improvements (willingness to pay by health and social care system
decision-makers). Each CEAC was derived using a net benefit approach. Monetary values of incremental
effects and incremental costs for each case were combined and net monetary benefit (NMB) derived as:
NMB= λ (effectb− effecta)− (costb− costa), (1)
where NMB was net monetary benefit, λ is willingness to pay for a 1-point difference in the outcome
measure (HADS-T score or QALYs) and subscripts a and b denote the TAU and START interventions,
respectively. We explored a range of λ values for each outcome. We were able to account for sampling
uncertainty and make adjustments as necessary in the primary analyses and sensitivity analyses.
For the cost-effectiveness analyses carried out at 24 months’ follow-up, costs and outcomes in the second
year were discounted at a rate of 3.5%, as recommended by NICE.51 The discount rate was varied from
0% to 6% to assess the impact changing the NICE-recommended rate had on costs, outcome and
the ICER.
Two sensitivity analyses were conducted to assess the robustness of our results. The first sensitivity analysis
adjusted for those variables which predicted missing outcomes, HADS-T score and QALYs, and was
investigated separately for each outcome using logistic regression. The first step was to model a binary
variable (missing vs. not missing) in bivariate logistic regression with each baseline demographic variable.
Those variables identified as significantly associated with missing were then used in multivariate logistic
regression to determine which remained significant. The main analyses were then repeated, adjusting for
those factors which were found to be associated with ‘missingness’ on each outcome. For the analysis of
HADS-T scores, the variables found to be associated with ‘missingness’ were patient living with carer,
relationship to carer, carer having children at home, patient ethnicity and COPE dysfunction score.
For the QALY outcome, the carer’s work situation (employed vs. unemployed) and ethnicity were
associated with ‘missingness’.
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A second sensitivity analysis adjusted for imbalances in baseline characteristics between the treatment
groups that occurred despite randomisation [i.e. adjusting for carers’ work situation, relationship to
patient, and patients’ and carers’ education and living situation (coresident or living separately)].
These analyses were chosen so as to be consistent with those used in the effectiveness analysis.41
We also plotted the CIs around the NMB to estimate the impact of uncertainty.
All economic analyses were carried out using Stata, version 12 (StataCorp LP, Chicago, IL, USA).
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Chapter 5 Results
Participant flow and recruitment
Two hundred and sixty (55%) of the 472 carers referred were randomised (CIFT= 182, NELFT= 16,
DRC= 35, NEPFT= 27) to the trial. The others declined to participate (n= 181; 38%), did not meet
inclusion criteria (n= 22; 5%) or were uncontactable (n= 9; 2%).
Short-term clinical results (over 8 months)
The flow through the study to the short-term (8-month) outcome is shown in the Consolidated Standards
of Reporting Trials (CONSORT) diagram (Figure 1).
Participant flow through study
Over the 8-month follow-up, 12 carers from the control group and 21 from the intervention group
withdrew or were lost to follow-up (see Figure 1). These included two who died (one from each group). In
the intervention group, one carer gave inconsistent data and was withdrawn by the team and one was in
prison. The participants gave the following reasons for withdrawal: wanted treatment but not allocated to
it (four in TAU group), did not feel the intervention was for them (three in intervention group), too busy
(four in intervention group, one in TAU group), disliked talking about care recipient when they were not
there (one in TAU group, one in intervention group), other family member wanted them to withdraw
(one in TAU group), unwell (one in intervention group), care recipient died (one in TAU group) and trial
too upsetting (one in intervention group). Six gave no reason (five in intervention group, one in TAU
group). Three others did not participate and were not contactable at the 4- or 8-month follow-up,
but have since come back to the study.
External validity
Table 1 compares the known demographic details of those who consented and those who did not and
shows that the study sample had good external validity. Those who consented were, however, slightly
more likely to be married to the care recipient than those who did not consent.
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Assessed for eligibility 
(N = 472)
Analysed for primary outcome (n = 152; 87.9%)
• Excluded from analysis, n = 21
     Withdrew, n = 11
     Missing data, n = 7
     Carer died, n = 1
     Inconsistent data, n = 1
     Imprisoned, n = 1
Lost to 4-month follow-up (n = 13)
• Carer died, n = 1
• Withdrawn, n = 10
• Inconsistent data, n = 1
• Imprisoned, n = 1
Allocated to intervention (n = 173)
• Received at least one session, n = 166
• Received at least five sessions, n = 130
Lost to 4-month follow-up (n = 10)
• Carer died, n = 1
• Withdrawn, n = 9
Allocated to TAU (n = 87)
• Received allocated intervention, n = 87
Analysed for primary outcome (n = 77; 88.5%)
• Excluded from analysis, n = 10
     Withdrew, n = 9
     Carer died, n = 1
Allocation
Primary analysisa
4-month follow-up
Randomised 
(n = 260)
Enrolment
Further losses by 8-month follow-up (n = 8)
• Withdrawn, n = 8
Further losses by 8-month follow-up (n = 2)
• Withdrawn, n = 2
8-month follow-up
Excluded (n = 212)
• Not meeting inclusion criteria, n = 22
• Declined to participate, n = 181
• Could not contact, n = 9
FIGURE 1 The CONSORT flow diagram (short-term analysis). a, To be included in the primary short-term analysis,
the individual must have at least one score available for the HADS at 4 or 8 months. Those excluded have no
measurements for either.
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Baseline data
One hundred and seventy-three (66.5%) participants were randomised to the intervention group and 87
were randomised to TAU. Details are shown in Table 2. In general, randomisation achieved good balance
for patient and baseline carer demographic and clinical characteristics between the randomised groups
(Tables 2 and 3).
Intervention
Therapists
We trained 10 psychology graduates with no further clinical training – seven women and three men – who
were ethnically white British (eight) and black and minority ethnic (two) in the age range 23–33 years.
They worked with between 11 and 32 participants each (mean 17.3 participants) (Table 4).
Adherence with therapy
Of the eight therapy sessions offered, five or more were attended by 130 (75.1%) carers in the
intervention group (Figure 2 shows details of number of sessions attended). Seven (4.0%) of those in
the intervention group withdrew before taking part in any therapy sessions. Adherence (attending five or
more sessions) was better in those of white ethnicity [110 (78.0%) vs. 19 (61.3%)] than in those of
other ethnicity and slightly better for male carers [46 (80.7%) vs. 84 (72.4%) of female carers] and those with
at least A-level education [56 (80.0%) vs. 74 (71.8%)]. Adherence was similar by age group [aged < 60–75
years (77.3%) vs. 55 years (73.3%)] and work situation [in paid work 49 (77.8%) vs. other 81 (73.6%)].
Fidelity
Double rating was carried out for the first 13 participants; these had a Cohen’s kappa value of 0.77, which
is substantial agreement.52 After this, we judged it was necessary to have only a single rating for the
remaining participants. Fidelity rating was carried out for 128 (78%) of the 165 participants who received
one or more intervention(s). The remaining 38 either refused to be audiotaped (10) or withdrew before
TABLE 1 External validity of eligible carers who consented to the trial compared with those who were
not randomised
Demographics Carers eligible but not randomised (n= 190) Carers randomised (n= 260)
Carer sex
Male 56 (29%) 82 (32%)
Patient sex
Male 75 (39%) 108 (42%)
Patient relationship to carer
Spouse/partner 65 (34%) 109 (42%)
Child 90 (47%) 113 (43%)
Friend 8 (4%) 6 (2%)
Daughter’s/son’s partner 4 (2%) 12 (5%)
Nephew/niece 8 (4%) 8 (3%)
Grandchild 4 (2%) 6 (2%)
Sibling 5 (3%) 4 (2%)
Other 6 (3%) 2 (1%)
Values are numbers (%) of carers.
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TABLE 2 Baseline carer and patient demographic characteristics by randomisation group
Demographics
Carer Patient
TAU Intervention TAU Intervention
Mean (SD), minimum, maximum Mean (SD), minimum, maximum
Age (years) 56.1 (12.3), 27,
89 (n= 87)
62.0 (14.6), 18,
88 (n= 172)
78.0 (9.9), 53,
96 (n= 87)
79.9 (8.3), 55,
95 (n= 173)
n (%) n (%)
Sex
Female 62 (71.3%) 116 (67.1%) 50 (57.5%) 102 (59.0%)
Male 25 (28.7%) 57 (32.9%) 37 (42.5%) 71 (41.0%)
Total 87 173 87 173
Ethnicity
White UK 65 (74.7%) 131 (76.2%) 61 (70.1%) 126 (72.8%)
White other 5 (5.7%) 10 (5.8%) 6 (6.9%) 14 (8.1%)
Black and
minority
17 (19.5%) 31 (18.0%) 20 (23.0%) 33 (19.1%)
Total 87 172a 87 173
Marital status
Not currently
married
25 (28.7%) 61 (35.3%) 47 (54.0%) 92 (53.2%)
Married/common
law
62 (71.3%) 112 (64.7%) 40 (46.0%) 81 (46.8%)
Total 87 173 87 173
Education
No qualifications 18 (20.7%) 45 (26.0%) 44 (51.2%) 73 (44.5%)
School-level
qualification
33 (37.9%) 51 (29.5%) 16 (18.6%) 28 (17.1%)
Further
education
36 (41.4%) 77 (44.5%) 26 (30.2%) 63 (38.4%)
Total 87 173 86 164
Work situation
Full-time 28 (32.2%) 36 (20.8%) N/A N/A
Part-time 20 (23.0%) 27 (15.6%) N/A N/A
Retired 23 (26.4%) 80 (46.2%) N/A N/A
Not working 16 (18.4%) 30 (17.3%) N/A N/A
Total 87 173 N/A N/A
Living with carer
Yes N/A N/A 50 (57.5%) 113 (65.3%)
Total N/A N/A 87 173
N/A, not applicable.
a Data missing for one carer.
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
26
TABLE 3 Baseline carer and patient clinical characteristics by randomisation group
Scale
Carer Patient
TAU Intervention TAU Intervention
HADS-T scoresa 14.8 (7.4) (n= 87) 13.5 (7.3) (n= 172) N/A N/A
HADS-A scoresa 9.3 (4.3) (n= 87) 8.1 (4.4) (n= 172) N/A N/A
HADS-D scoresa 5.5 (3.9) (n= 87) 5.4 (3.8) (n= 172) N/A N/A
QoL-AD scoresa N/A N/A 29.9 (6.9) (n= 87) 30.2 (6.9) (n= 170)
HSQ mental health
scoresa
58.2 (21.7) (n= 87) 58.3 (22.4) (n=171) N/A N/A
MCTS total scoresa 2.7 (3.1) (n= 87) 2.5 (2.9) (n=172) N/A N/A
Zarit total scoresa 38.1 (17.0) (n= 84) 35.3 (18.4) (n= 165) N/A N/A
NPI total scoresa N/A N/A 26.6 (20.1) (n= 86) 24.0 (19.0) (n= 171)
CDR overall scoreb N/A N/A (n= 87) (n= 171)
Score 0.5 N/A N/A 12 (13.8%) 30 (17.5%)
Score 1 N/A N/A 43 (49.4%) 91 (53.2%)
Score 2 N/A N/A 30 (34.5%) 48 (28.1%)
Score 3 N/A N/A 2 (2.3%) 2 (1.2%)
HADS-A case
(score of ≥ 9)b
48 (55.2%) (n= 87) 85 (49.4%) (n= 172) N/A N/A
HADS-D case
(score of ≥ 9)b
17 (19.5%) (n= 87) 36 (20.9%) (n= 172) N/A N/A
MCTS (at least
one item with
score of ≥ 2)b
38 (43.7%) (n= 87) 82 (47.7%) (n= 172) N/A N/A
N/A, not applicable.
a Data are mean (SD).
b Data are number (percentage).
TABLE 4 Number of carers by therapist (intervention group)
Therapist Number of carers (%)
1 11 (6.4)
2 21 (12.1)
3 12 (6.9)
4 19 (11.0)
5 12 (6.9)
6 11 (6.4)
7 32 (18.5)
8 21 (12.1)
9 17 (9.8)
10 17 (9.8)
Total 173 (100.0)
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carrying out the session which had been randomly selected for assessment (n= 28). For 100 (78%)
participants fidelity was rated as 5, for 20 (16%) it was rated as 4, for five it was rated as 3 and for three it
was rated as 2. Overall mean fidelity was calculated by adding each average rating (rating 1 plus rating 2,
divided by 2) of the first 13 participants to the ratings of the remaining 105 participants, and dividing by the
overall number of participants with available fidelity ratings. The mean fidelity score was 4.7 (SD 0.66).
Languages, translation and interpreters
Four eligible participants used translators at the recruitment stage, in Turkish (one), Bengali (two) and Farsi
(one), and all four consented and were randomised: three to intervention and one to TAU. One participant
allocated to intervention changed his or her mind and withdrew from intervention before session 1 but not
follow-ups; one completed five sessions and one completed eight sessions.
Missing outcome data
The proportion of missing data for the main trial outcomes is given in Table 5 by group and follow-up time.
The primary outcome (HADS-T score) was missing for 35 (13.5%) patients at 4 months and for 56 (21.5%)
patients at 8 months, with a slightly higher proportion missing in the intervention group: 40 (23.0%) in the
intervention group and 16 (18.0%) in the TAU group. Two hundred and twenty-nine (88.1%) had HADS-T
data for at least one of the 4- and 8-month points and, so, could be included in the primary analyses. Using
logistic regression models, we identified baseline factors that were associated with missing outcome data.
Missingness of HADS-T score at 4 months was associated with the patient living with carer (p= 0.007)
and for the 8-month outcome with having dependent children at home (p= 0.003), patient ethnicity
(p= 0.013), patient living with carer (p= 0.002), patient relationship to carer (p= 0.011) and the COPE
dysfunction score (p= 0.004).
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FIGURE 2 Number of sessions completed by participants.
TABLE 5 Percentage missing outcome by follow-up and group
Scale
Baseline 4 months 8 months
TAU, %
missing
Intervention,
% missing
TAU, %
missing
Intervention,
% missing
TAU, %
missing
Intervention,
% missing
HADS-A 0.0 0.6 13.8 13.3 18.4 23.1
HADS-D 0.0 0.6 13.8 13.3 18.4 23.1
HADS-T 0.0 0.6 13.8 13.3 18.4 23.1
Zarit total 3.4 4.6 26.4 20.2 31.0 32.4
MCTS total 0.0 0.6 20.7 20.2 26.4 30.6
HSQ mental health 0.0 1.2 17.2 16.8 24.1 29.5
QoL-AD total 0.0 1.7 24.1 20.8 29.9 30.6
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Clinical outcomes
Primary outcome
Analysis of HADS-T, adjusting for trust and baseline score and for factors related to outcome (carer age
and sex, NPI and Zarit scores), showed a mean difference of –1.80 points (95% CI –3.29 to –0.31 points;
p= 0.02) in favour of the intervention (Table 6). If the model did not include factors relating to outcome,
then the results were similar, with an average decrease in score of –1.46 points (95% CI –2.89 to
–0.03 points; p= 0.05). There was little therapist clustering: ICC at 4 months was 0.02 (95% CI 0.00 to
0.09) and at 8 months was 0.00 (95% CI 0.00 to 0.08).
Model assumptions were examined by checking the normality of the residuals and also plotting the
residuals compared with the fitted values. These were done at the individual and therapist cluster level.
These plots are shown in Figure 3 and do not indicate concerns about the model fit.
Sensitivity analysis
For the sensitivity analysis we adjusted for baseline factors associated with missingness of the HADS-T
outcome. Missingness of the 4-month HADS-T was associated with patient living with carer (p= 0.007) and
TABLE 6 Primary and secondary clinical outcomes for the intervention and TAU groups (at 4 and 8 months):
primary and secondary outcomes (at 4 and 8 months)
Measure
TAU TAU Intervention Intervention Adjusted for
baseline score
and centre,
difference
(95% CI)
Adjusted also
for carers age,
sex, NPI and
Zarit, difference
(95% CI)
4 months,
mean (SD)
8 months,
mean (SD)
4 months,
mean (SD)
8 months,
mean (SD)
HADS-T scores 14.3 (7.4)
(n= 75)
14.9 (8.0)
(n= 71)
12.4 (7.4)
(n= 150)
12.9 (7.9)
(n= 133)
–1.46
(–2.89 to –0.03;
p-value= 0.05)
(n= 229)
–1.80
(–3.29 to –0.31;
p-value= 0.02)
(n= 220)
QoL-AD scores 29.8 (5.8)
(n= 66)
29.7 (6.3)
(n= 61)
30.6 (6.4)
(n= 136)
30.2 (7.2)
(n= 119)
0.80
(–0.45 to 2.05)
(n= 205)
0.59
(–0.72 to 1.89)
(n= 197)
HSQ mental
health scores
58.4 (18.0)
(n= 72)
58.2 (19.2)
(n= 66)
62.7 (20.8)
(n= 144)
58.6 (22.0)
(n= 122)
4.55
(0.92 to 8.17)
(n= 219)
4.09
(0.34 to 7.83)
(n= 211)
HADS-A scores 8.6 (4.2)
(n= 75)
8.8 (4.4)
(n= 71)
7.5 (4.2)
(n= 150)
7.6 (4.4)
(n= 133)
–0.62
(–1.43 to 0.19)
(n= 229)
–0.91
(–1.76 to –0.07)
(n= 220)
HADS-D scores 5.7 (4.0)
(n= 75)
6.1 (4.2)
(n= 71)
4.9 (3.9)
(n= 150)
5.3 (4.0)
(n= 133)
–0.88
(–1.68 to –0.09)
(n= 229)
–0.91
(–1.71 to –0.10)
(n= 220)
HADS-A case
(score of ≥ 9)
36 (48.0%)
(n= 75)a
33 (46.5%)
(n= 71)a
54 (36.0%)
(n= 150)a
53 (39.9%)
(n= 133)a
0.35
(0.11 to 1.18)
(n= 229)b
0.30
(0.08 to 1.05)
(n= 220)b
HADS-D case
(score of ≥ 9)
18 (24.0%)
(n= 75)a
23 (32.4%)
(n= 71)a
25 (16.7%)
(n= 150)a
28 (21.1%)
(n= 133)a
0.25
(0.08 to 0.81)
(n= 229)b
0.24
(0.07 to 0.76)
(n= 220)b
MCTS (at least
one item with
score of ≥ 2)
28 (40.6%)
(n= 69)a
23 (35.9%)
(n= 64)a
50 (36.0%)
(n= 139)a
40 (33.3%)
(n= 120)a
0.47
(0.18 to 1.23)
(n= 214)b
0.48
(0.18 to 1.27)
(n= 206)b
a Data are numbers of people and per cent.
b Data are odds ratios and 95% CIs.
Values are means (SD) unless otherwise stated. Treatment effect estimates (differences and odds ratios) are from models
which take into account the repeated measurements, therapist clustering in the intervention arm and which are adjusted
for baseline characteristics.
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FIGURE 3 Checking model assumptions: residuals and fitted values from the models for HADS-T (based on the
model-adjusted only for centre and baseline score). (a) Normality of residuals (individual level); (b) residuals vs.
fitted values (individual level); (c) normality of residuals (cluster level); and (d) residuals vs. fitted values
(cluster level).
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for the 8-month outcome with having dependent children at home (p= 0.003), patient ethnicity (p= 0.01),
patient living with carer (p= 0.002), patient relationship to carer (p= 0.010) and the COPE dysfunction
score (p= 0.004). Refitting the main models adjusting for these significant predictors of missing values did
not have a significant impact on the results (mean difference –1.53, 95% CI –2.96 to –0.10). We also
carried out a sensitivity analysis to adjust for baseline imbalances, namely carer’s work situation, relationship
to carer and patient and carer education and living situation, which again gave similar conclusions (mean
difference –1.78, 95% CI –3.30 to –0.27). Models including an interaction with time showed no evidence
of a differential effect of the intervention between the 4- and 8-month time points (p= 0.90).
Secondary outcomes
Depression and anxiety caseness on the HADS
There was a significant reduction in the odds of HADS-D cases in the intervention group compared with TAU,
with an odds four times higher for the TAU group [adjusted odds ratio (OR) 0.24, 95% CI 0.07 to 0.76].
Similarly, there was some evidence for a reduction in odds of HADS-A caseness (OR 0.30, 95% CI 0.08 to 1.05).
Anxiety and depression symptoms
Adjusted models for the individual HADS-A and HADS-D continuous scales indicated significant beneficial
effects of the intervention over 8 months, with average decreases in scores of –0.910 (95% CI –1.763 to
–0.070) and –0.91 (95% CI –1.71 to –0.10), respectively.
For HADS-A, sensitivity analyses adjusting for significant demographic and clinical predictors of missing
values, namely patient living with carer, relationship to carer, carer having dependent children at home,
patient ethnicity and COPE dysfunction score, gave a result with no significant difference between groups
(mean difference –0.68, 95% CI –1.49 to 0.11; n= 229).
The same analysis of HADS-D showed a significant difference between groups (mean difference –0.90,
95% CI –1.70 to –0.11; n= 229).
Models including an interaction with time showed no evidence of a differential effect of the intervention
between the 4- and 8-month time points for either HADS-A or HADS-D.
Carer (Health Status Questionnaire) and care recipient (Quality of
Life-Alzheimer’s disease) quality of life
There was no significant difference between groups in the person with dementia’s overall QoL (QoL-AD).
The HSQ mental health scale for the carer did, however, indicate significantly higher average scores and,
hence, improved mental health (mean difference 4.09, 95% CI 0.34 to 7.83).
Models including an interaction with time showed no evidence of a differential effect of the intervention
between the 4- and 8-month time points for either the HSQ mental health or the QoL-AD.
Modified Conflict Tactics Scale for significant abuse
There was some evidence of a decrease in abusive behaviour (OR 0.48, 95% CI 0.18 to 1.27). There was no
evidence of an interaction between the intervention and the outcome at the 4- and 8-month follow-ups.
Time to care home admission
Fourteen patients were admitted to a care home during the 8-month follow-up period (not included in
Table 7): three (3.6%) in the TAU group and 11 (6.4%) in the intervention group. Simple analyses indicate
no evidence of a statistically significant difference between the groups (Fisher’s exact test, p= 0.56).
This outcome will be considered more extensively in analyses of longer-term follow-up.
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Health economic analysis: short term over 8 months
Service use and costs
Carers used a wide range of health and social care services over the 8-month period, as can be seen in
Table 7. We did not impute individual items of service use and means are presented for non-missing cases
only. Outpatient hospital and GP services were used by quite high proportions of participants.
The patterns of service use were weighted by their unit costs. Mean costs – grouped into outpatient,
community and other services – are given in Table 8. The table distinguishes between the START and TAU
groups, and reports figures for two time periods: the 4-month period between baseline and the 4-month
assessment, and the 4-month period between the 4- and 8-month assessments. Although the number of
users of outpatient services was higher in the intervention group (see Table 8), their average outpatient
service cost was lower as they used outpatient services less frequently than people in the TAU group.
TABLE 7 Carers’ use of health and social care services at baseline, 4 months and 8 months
Service
Baseline, % (n) 4 months, % (n) 8 months, % (n)
TAU
(N= 87)
Intervention
(N= 173)
TAU
(N= 75)
Intervention
(N= 150)
TAU
(N= 71)
Intervention
(N= 134)
Outpatient services
Outpatient hospital
services
33.3 (29) 37.0 (64) 32.0 (24) 38.7 (58) 28.2 (20) 37.3 (50)
Community-based services
Admiral Nurse 5.7 (5) 3.5 (6) 2.6 (2) 6.0 (9) 2.8 (2) 3.7 (5)
Chiropodist 5.7 (5) 13.9 (24) 9.3 (7) 11.3 (17) 12.7 (9) 17.2 (23)
Counsellor 8.0 (7) 2.3 (4) 9.3 (7) 2.7 (4) 11.3 (8) 1.5 (2)
Dentist 27.6 (24) 30.6 (53) 29.3 (22) 30.7 (46) 36.6 (26) 33.6 (45)
GP 54.0 (47) 54.3 (94) 53.3 (40) 50.0 (75) 47.9 (34) 48.5 (65)
NHS Direct 1.1 (1) 1.2 (2) 1.3 (1) 0.0 (0) 0.0 (0) 1.5 (2)
Optician 17.2 (15) 16.8 (29) 8.0 (6) 15.3 (23) 21.1 (15) 18.7 (25)
Outreach worker 1.1 (1) 0.6 (1) 0.0 (0) 0.7 (1) 1.4 (1) 0.0 (0)
Home care worker/
care attendant
2.3 (2) 1.7 (3) 4.0 (3) 1.3 (2) 1.4 (1) 1.5 (2)
Physiotherapist 0.0 (0) 0.6 (1) 1.3 (1) 0.0 (0) 0.0 (0) 2.2 (3)
Hygienist 0.0 (0) 0.6 (1) 0.0 (0) 0.7 (1) 1.4 (1) 0.7 (1)
Company medical
check-up
0.0 (0) 0.6 (1) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0)
Nurse (advanced) 1.1 (1) 0.6 (1) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0)
Occupational
therapist
0.0 (0) 0.6 (1) 0.0 (0) 0.7 (1) 0.0 (0) 0.0 (0)
Community
psychiatrist
0.0 (0) 0.6 (1) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0)
Practice nurse 6.9 (6) 2.3 (4) 2.6 (2) 4.7 (7) 0.0 (0) 5.2 (7)
Ambulance transport 0.0 (0) 0.0 (0) 0.0 (0) 0.7 (1) 0.0 (0) 0.0 (0)
Dietitian 0.0 (0) 0.0 (0) 0.0 (0) 0.7 (1) 0.0 (0) 0.0 (0)
Other services 16.1 (14) 9.8 (17) 22.7 (17) 14.0 (21) 12.7 (9) 13.4 (18)
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The right-hand column of Table 8 shows the difference in costs between the START and TAU groups
across the whole evaluation period of 8 months. Excluding the direct cost of the intervention itself, mean
costs over the study period (1–8 months) were £558 in the START group and £625 in the TAU group.
After adjustment for baseline characteristics (see above) the standardised difference was £14, with the
95% CI (–£239 to £211) suggesting that there was not a significant difference in costs between the two
groups. For purposes of comparison, scores on the two outcome measures used in the economic
evaluation are included towards the bottom of Table 8.
The calculation of cost of the therapy is based on the time spent by the 10 therapists in delivering
one-to-one therapy to carers, their own training sessions (40 sessions of 2.5 hours over a 6-week period),
time spent making telephone calls to participants, time spent writing up notes and supervision of the
therapists by the clinical psychologist (1.5 hours each per week for 8 weeks). Looking at the average time
spent in each session with the carer, excluding those who did not have any sessions and those who used
translators (n= 163), the median time per session was 1 hour 16 minutes (76 minutes). The mean time per
session was 1 hour 17 minutes (77 minutes, SD 20 minutes). For those who used translators, the mean
time per session was 3 hours 47 minutes (SD 1 hour 36 minutes), with a range of 2 hours 40 minutes
to 4 hours 55 minutes. We calculated that the mean cost per session per carer was £36. Adding in the
cost of the relaxation CDs (which totalled £284), the overall mean direct intervention cost averaged
£232.15 per carer.
Including the cost of intervention itself in the comparison between the groups and adjusting for baseline
variables as we did in the clinical effectiveness calculations, costs for the START group were slightly but not
significantly higher than for the TAU group. The mean cost difference was £252 (95% CI –£28 to £565)
for sample members on the EQ-5D, and £247 (95% CI £0 to £569) for sample members on the HADS-T
measure (Table 9).
Cost-effectiveness
Results from the net benefit regression using the two outcomes examined in the economic evaluation
(QALYs and HADS-T score) are summarised and the ICERs reported in Table 10. The cost and outcome
differences are obtained after adjustment for baseline characteristics and are influenced slightly by size of
sample with complete data for each outcome.
TABLE 8 Health and social service costs and outcomes at 4 and 8 months for carers in the intervention and TAU
groups, and differences between START and TAU groups
Cost categories and
outcomes used in the
economic evaluation
TAU, mean (SD) Intervention, mean (SD) Intervention vs. TAU over
1–8 months, difference
(95% CI) adjusted for
baseline variables1–4 months 5–8 months 1–4 months 5–8 months
Costs (£, 2009–10)
Outpatient 140 (428) 125 (385) 99 (183) 99 (237) –42 (–118 to 34)
Community 107 (148) 110 (153) 101 (180) 96 (153) –7 (–34 to 19)
Other 134 (1028) 9 (36) 96 (845) 68 (461) 27 (–151 to 205)
Total 381 (1102) 244 (450) 296 (1006) 262 (598) –14 (–239 to 211) (n= 193)
Outcomes used in the economic evaluation
HADS-T scoresa 14.3 (7.4) 14.9 (8.0) 12.4 (7.4) 12.9 (7.9) –1.79 (–3.22 to –0.37) (n= 220)
EQ-5D 0.77 (0.23) 0.79 (0.14) 0.77 (0.22) 0.76 (0.24) 0.03 (–0.01 to 0.08) (n= 212)
Direct cost of intervention not included.
a HADS-T scores and difference are slightly different from above because different versions of Stata were used for
the analyses.
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Health and social care system costs were slightly higher for carers who received the START intervention
(in addition to TAU) but the difference was not statistically significant, and carers in this group enjoyed
significantly better outcomes, whether measured in terms of health-related QoL (QALY) or affective
symptoms (HADS-T). Whether or not these results imply that START is cost-effective compared with TAU
depends on the decision-maker’s willingness to pay for these gains in QoL and affective symptoms. To aid
discussion of willingness to pay, we computed the ICERs. We also plotted the associated CEACs and
examined the CIs around NMB.
Looking first at QALY as the outcome, the mean cost per QALY gained was £6000. The CEAC is shown in
Figure 4, illustrating the probability of cost-effectiveness for each of a number of different hypothesised
values of willingness to pay. At the £20,000 per QALY threshold associated with NICE recommendations,
TABLE 9 Treatment and cost effects (with 95% bias-corrected CIs) and ICERs over 8 months
Outcome
Incremental differences
(START minus TAU) and ICERs
over 8-month evaluation period
With QALY as outcome (n= 177)a
Incremental health and social care costs (£, 2009–10), mean (95% CI) £252 (–£28 to £565)
Incremental QALY gain, mean (95% CI) 0.042 (0.015 to 0.071)
ICER (£ per QALY) 6000
With HADS-T as outcome (n= 191)b
Incremental health and social care costs (£, 2009–10), mean (95% CI) £247 (£0 to £569)
Incremental HADS-T score change, mean (95% CI) 2.10 (0.51 to 3.75)
ICER (£ per unit change on HADS-T) £118
a Sample size based on complete data for QALYs and cost measures.
b Sample size based on complete data for HADS-T and cost measures.
TABLE 10 Sensitivity analyses: treatment and cost effects (with 95% CIs) and ICERs over 8 months
Outcome
Incremental differences and ICERs over 8-month
evaluation period
Adjusting for significant
demographic and clinical
predictors of missing values
Adjusting for baseline
imbalances
With QALY as outcome (n= 177)a
Incremental health and social care costs (£, 2009–10),
mean (95% CI)
£229 (–£94 to £552) £236 (–£101 to £617)
Incremental QALY gain, mean (95% CI) 0.042 (0.014 to 0.070) 0.041 (0.012 to 0.071)
ICER (£ per QALY) £5452 £5756
With HADS-T as outcome (n= 191)b
Incremental health and social care costs (£, 2009–10),
mean (95% CI)
£226 (–£74 to £525) £231 (–£46 to £583)
Incremental HADS-T score change, mean (95% CI) 2.11 (0.41 to 3.81) 2.07 (0.44 to 3.90)
ICER (£ per unit change on HADS-T) £107 £112
a Sample size based on complete data for QALYs and cost measures.
b Sample size based on complete data for HADS-T and cost measures.
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the probability that the START intervention would be seen as cost-effective was 93% and at the higher
NICE threshold of £30,000 it was 99%.53
The 95% CIs around NMB suggest that there is a strong likelihood that the START intervention is
cost-effective at the £30,000 threshold.
For the other outcome measure, the HADS-T measure of affective symptoms, the mean cost per 1-point
difference on the HADS-T was £118. The CEAC for this outcome measure is shown in Figure 5.
We are not aware of any previously suggested monetary thresholds for gauging cost-effectiveness on
the HADS. However, if we assumed a willingness to pay of £500, the probability that the START
intervention would be seen as cost-effective would be 95%. We can also refer to a previous suggestion
that a minimally important clinical difference on the HADS-T is 1.6. The mean cost of achieving such a
change with the START intervention would be £189.
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FIGURE 4 Cost-effectiveness acceptability curve: START intervention (manual-based coping strategy therapy)
vs. TAU; health and social care perspective, with effectiveness measured in QALY gain over 8 months.
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FIGURE 5 Cost-effectiveness acceptability curve: START intervention (manual-based coping strategy therapy)
vs. TAU; health and social care perspective, with effectiveness measured in HADS gain over 8 months.
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Sensitivity analyses
The first sensitivity analysis adjusted for significant baseline differences on demographic and clinical
predictors of missing values. The results were similar to those from the primary analyses and are
summarised in the first column of figures in Table 10.
The mean ICER values are now £5452 per additional QALY and £107 per 1-point difference in HADS-T
score. Figure 6 shows the CEAC with QALY as the outcome measure; at the lower-bound NICE threshold
of £20,000, the START intervention has an approximately 95% likelihood of being seen as cost-effective,
rising to 98% at the £30,000 threshold.
The second sensitivity analysis adjusted for imbalances in baseline characteristics. The results were again
quite similar to those from the primary analyses and are summarised in the second column of figures
in Table 11. The mean ICER values from this further analysis are £5756 per additional QALY, and £112 per
1-point difference in HADS-T score.
The CEAC with QALY as the outcome measure is shown in Figure 6. At the lower-bound NICE threshold
of £20,000, the START intervention has a 93% likelihood of being seen as cost-effective, rising to 98% at
the £30,000 threshold.
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FIGURE 6 Sensitivity analysis of CEAC with QALY as the outcome measure over 8 months.
TABLE 11 Missing outcomes at 12 and 24 months’ follow-up
Measure
Missing at 12 months, n (%) Missing at 24 months, n (%)
Randomised group Randomised group
TAU Intervention TAU Intervention
HADS-A 20 (23) 35 (20) 23 (26) 41 (24)
HADS-D 20 (23) 35 (20) 23 (26) 41 (24)
HADS-T 20 (23) 35 (20) 23 (26) 41 (24)
MCTS total 32 (37) 59 (34) 40 (46) 78 (45)
HSQ mental health 26 (30) 52 (30) 32 (37) 60 (35)
QoL-AD total 34 (39) 58 (34) 38 (44) 77 (45)
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The CIs around NMB for these two sensitivity analyses are shown in Appendix 2. Taking into account
uncertainty in the estimation suggests that a degree of caution should be exercised in concluding that
START is necessarily cost-effective.
Long-term outcomes (12 and 24 months)
The CONSORT diagram (Figure 7) shows the flow of participants through the study up to the 2-year
follow-up. The primary outcome (HADS-T score) was missing for 55 (21.2%) patients at 12 months and for
64 (24.6%) patients at 24 months. Two hundred and nine (80.4%) patients had HADS-T data for at least
one of the long-term follow-up points, and so could be included in the primary analyses.
Missing outcomes
The proportion of missing data for the main trial outcomes is given in Table 11 by group and
follow-up time.
Clinical outcomes
Primary and secondary clinical outcomes are shown in Table 12. This summarises average scores at
months 12 and 24 and gives the estimated effect of therapy compared with TAU for primary and
secondary outcomes.
Analysis of HADS-T scores, adjusting for trust and baseline score and for factors related to outcome
(carer age and sex, NPI and Zarit scores), showed a mean difference of –2.58 points (95% CI –4.26 to
–0.90 points; p= 0.003) in favour of the intervention. If the model did not include factors relating
to outcome then the results were similar, with an average decrease in score of –1.84 (95% CI –3.50 to
–0.17; p= 0.03). The therapist ICC at 12 months was 0.00 (95% CI 0.00 to 0.07) and at 24 months was
0.00 (95% CI 0.00 to 0.07).
Sensitivity analyses adjusting for significant demographic and clinical predictors of missing values, namely
patient living with carer and COPE dysfunction score, still gave a result with significant difference between
groups (difference in means –2.69, 95% CI –4.39 to –0.98; p= 0.002; n= 200), as did sensitivity analyses
adjusting for factors imbalanced at baseline (carer work, carer education, patient education, relationship
with carer, lives with carer; difference in means –2.37, 95% CI –4.11 to –0.63, p= 0.008).
Models including an interaction with time showed no evidence of a differential effect of the intervention
between the 4- and 8-month time points or between the 12- and 24-month time points for HADS-T score
(p= 0.92) and indicated a similar long-term treatment effect.
Model assumptions were examined by checking plots assessing the normality of the residuals and also
plotting residuals versus fitted values. These were done for residuals at both the individual and the
therapist cluster level. These plots did not indicate concerns about the model fit.
Secondary outcomes
Results of models considering the long-term effect of intervention on secondary outcomes are also
given in Table 12.
Depression and anxiety caseness on the HADS
From the adjusted models there was a significant reduction in the odds of HADS-D cases in the
intervention group compared with TAU, with an odds seven times higher for the TAU group (OR 0.14,
95% CI 0.04 to 0.53). Similarly, there was some evidence for a reduction in odds of HADS-A caseness
(OR 0.57, 95% CI 0.26 to 1.24).
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Assessed for eligibility
(N = 472)
Excluded (n = 212)
• Not meeting inclusion criteria, n = 22
• Declined to participate, n = 181
• Could not contact, n = 9
Further losses by 12-month follow-up (n = 8)
• Carer died, n = 1
• Withdrawn, n = 6
• Prevented, n = 1
Lost to 4-month follow-up (n = 13)
• Carer died, n = 1
• Withdrawn, n = 10
• Inconsistent data, n = 1
• Prevented, n = 1
Allocated to intervention (n = 173)
• Received at least one session, n = 166
• Received at least five sessions, n = 130
Lost to 4-month follow-up (n = 10)
• Carer died, n = 1
• Withdrawn, n = 9
Allocated to TAU (n = 87)
• Received allocated intervention, n = 87 
Further losses by 12-month follow-up (n = 5) 
• Withdrawn, n = 5
Allocation
12-month follow-up
4-month follow-up
Randomised
(n = 260)
Enrolment
Further losses by 8-month follow-up (n = 8)
• Withdrawn, n = 8
Further losses by 8-month follow-up (n = 2)
• Withdrawn, n = 2
8-month follow-up
Analysed for primary outcome (n = 140)
• Excluded from analysis, n = 33
    Withdrew, n = 27
    Carer died, n = 4
    Inconsistent data, n = 1
    Prevented, n = 1
Analysed for primary outcome (n = 69)
• Excluded from analysis, n = 18
    Withdrew, n = 17
    Carer died, n = 1
Primary analysisa
Further losses by 24-month follow-up (n = 12)
• Carer died, n = 3
• Withdrawn, n = 9
Further losses by 24-month follow-up (n = 6)
• Withdrawn, n = 6
24-month follow-up
FIGURE 7 The CONSORT flow diagram for long-term outcomes (12 and 24 months). a, To be included in the
primary long-term analysis, the individual must have at least one score available for the HADS at 12 or 24 months.
Those excluded have no measurements at 12 or 24 months.
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Anxiety and depression symptoms
Adjusted models for the individual HADS-A and HADS-D continuous scales indicated significant beneficial
effects of the intervention at 24 months, with average decreases in scores of –1.16 (–2.15 to –0.18;
n= 200) and –1.45 (95% CI –2.32 to –0.57), respectively.
Models including an interaction with time showed no evidence of a differential effect of the intervention
between the 4- and 8-month time points or between the 12- and 24-month time points for HADS-A or
HADS-D (p= 0.99 and p= 0.86, respectively).
TABLE 12 Primary and secondary clinical outcomes (at 12 and 24 months): primary and secondary outcomes
(at months 12 and 24) for those in the intervention and TAU groups
Measure
TAU Intervention Adjusted for
baseline score
and centre,
difference
(95% CI)
Adjusted also
for carer’s age,
sex, NPI and
Zarit, difference
(95% CI)
12 months,
mean (SD)
24 months,
mean (SD)
12 months,
mean (SD)
24 months,
mean (SD)
HADS-T scores 14.6 (8.9)
(n= 64)
15.5 (9.5)
(n= 64)
12.5 (7.9)
(n= 138)
13.6 (8.3)
(n= 132)
–1.84
(–3.50 to –0.17)b
(n= 209)
–2.58
(–4.26 to –0.90)b
(n= 200)
QoL-AD scores 30.0 (6.4)
(n= 53)
29.4 (7.0)
(n= 49)
30.5 (6.7)
(n= 114)
29.9 (6.7)
(n= 95)
0.16
(–1.30 to 1.63)b
(n= 174)
0.17
(–1.37 to 1.70)b
(n= 168)
HSQ mental
health scores
56.2 (22.5)
(n= 61)
55.0 (21.2)
(n= 55)
61.9 (20.6)
(n= 121)
60.2 (19.8)
(n= 113)
7.16
(2.72 to 11.60)
(n= 189)
7.47
(2.87 to 12.08)b
(n= 183)
HADS-A scores 8.8 (5.1)
(n= 67)
9.2 (5.3)
(n= 64)
7.5 (4.4)
(n= 138)
8.1 (4.9)
(n= 132)
–0.75
(–1.75 to 0.25)b
(n= 209)
–1.16
(–2.15 to –0.18)b
(n= 200)
HADS-D scores 5.9 (4.3)
(n= 67)
6.3 (4.9)
(n= 64)
5.0 (4.2)
(n= 138)
5.5 (4.2)
(n= 132)
–1.14
(–2.00 to –0.28)b
(n= 209)
–1.45
(–2.32 to –0.57)b
(n= 200)
HADS-A case
(score of ≥ 9)
33 (49.3)a
(n= 67)
32 (50.0)a
(n= 64)
54 (39.1)a
(n= 138)
57 (43.2)a
(n= 132)
0.53
(0.24 to 1.16)c
(n= 209)
0.57
(0.26 to 1.24)c
(n= 200)
HADS-D case
(score of ≥ 9)
18 (26.9)a
(n= 67)
19 (29.7)a
(n= 64)
24 (17.4)a
(n= 138)
30 (22.7)a
(n= 132)
0.22
(0.05 to 0.96)c
(n= 209)
0.14
(0.04 to 0.53)c
(n= 192)
MCTS (at least
one item with
score of ≥ 2)
21 (38.2)a
(n= 55)
11 (23.4)a
(n= 47)
41 (36.0)a
(n= 114)
28 (29.5)a
(n= 95)
0.96
(0.42 to 2.19)c
(n= 176)
0.83
(0.36 to 1.93)c
(n= 171)
a Data are numbers and percentages.
b Data are treatment effect (intervention – TAU) with 95% CIs.
c Data are ORs and 95% CI.
Values are means (SD) unless otherwise stated. Treatment effect estimates (differences and ORs) are from models which
take into account the repeated measurements, therapist clustering in the intervention arm and which are adjusted for
baseline characteristics.
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Carer (Health Status Questionnaire) and care recipient (Quality of
Life-Alzheimer’s disease) quality of life
There was no significant difference between groups for the person with dementia’s overall QoL (QoL-AD).
The HSQ mental health scale for the carer did, however, indicate significantly higher average scores and
hence improved mental health (mean difference 7.47, 95% CI 2.87 to 12.08; n= 183).
Models including an interaction with time showed no evidence of a differential effect of the intervention
between the 4- and 8-month time points or between the 12- and 24-month time points for either QoL-AD
or HSQ mental health (p= 0.24 and p= 0.14, respectively).
Time to care home admission
Two hundred and fifty-nine (87 in TAU and 172 in the intervention group) individuals were included in the
analysis. We found that one person with dementia was included twice as two different carers (spouse and
daughter) had been included and gave different dates of birth of the patient. The individual was included
only once and from the first recruitment date (spouse carer’s recruitment). Both carers had been in the
intervention group.
For four people (three in TAU and one in the intervention group), the baseline date and the last known at
home date were the same; thus, they were censored at time= 0 days.
Of the remaining 84 in the TAU group, 17 (20.2%) were admitted to a care home, and in the intervention
group, 32 (18.7%) of the remaining 171 were admitted, within the 24-month follow-up period.
Figure 8 shows a Kaplan–Meier plot for time until admission to a care home for each randomised group.
A parametric shared frailty model assuming a gamma distribution for the shared frailty with a Weibull
survival distribution was fitted for the time to institutionalisation. The model included trust and
randomisation group and additionally adjusted for carer age, carer sex, baseline NPI total and baseline Zarit
total. This model included 242 people with dementia. The estimated hazard ratio (HR) was 0.83 with
95% CI 0.44 to 1.56 (p= 0.56), showing no significant evidence of an effect of the intervention compared
with TAU. Sensitivity analyses fitted the same model with addition adjustment for baseline imbalances
(carer work, carer education, patient education, relationship with carer, lives with carer). This gave HR 0.62
(95% CI 0.31 to 1.23; p= 0.17; n= 232).
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FIGURE 8 Time until admission to a care home for each randomised group over 24 months’ follow-up.
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Modified Conflict Tactics Scale for significant abuse
There was no evidence for a decrease in abusive behaviour (adjusted OR 0.83, 95% CI 0.36 to 1.93)
(Figure 9).
Cost-effectiveness (over 24 months)
Service use and costs
Economic data for the 24-month follow-up period were available for 196 carers (75%): 64 in the TAU
group and 132 in the intervention group. The number of carers using services in the 24-month follow-up
period is detailed in Table 13. As can be seen in Table 13, carers used a wide range of health and social
care services. GP services were used by a high proportion of participants.
Mean health and social care costs are reported in Table 14. The table distinguishes the START and TAU
groups and reports figures for the 4-month period from 9 to 12 months and the 4-month period from
21 to 24 months. In contrast to the outpatient service costs over the 4-month period between baseline
and the 4-month assessment and the 4-month period between the 4- and 8-month assessments,
outpatient service costs over 9–12 months and 21–24 months were higher in the intervention group as
participants in this group used outpatient services more frequently than those in the TAU group.
Table 14 shows the difference in costs between the START and TAU groups across the whole evaluation
period of 24 months. To calculate costs over 24 months, we summed costs over the study periods
1–8 months, 9–12 months, 13–20 months and 21–24 months. Costs during the period between the
12- and 21-month data collection time points (on average 8 months) were interpolated from 12- and
24-month data. Mean costs over the study period (1–24 months) were £1492 in the START group and
£1578 in the TAU group. After adjustment of baseline characteristics, the standardised difference was
£173, with the 95% CI (–£115 to £460) suggesting that there was no significant difference in costs
between the two groups. The scores on the two outcome measures used in the economic evaluation are
included at the bottom of Table 14.
Mean costs (including the direct costs of intervention and health and social care system costs) for the
24-month period for carers in the START group were higher, although not significantly so, than for carers
in the TAU group. The mean cost difference was £336 (95% CI –£223 to £895) for sample members
on the EQ-5D and £303 (95% CI –£206 to £812) for sample members on the HADS-T measure (Table 15).
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FIGURE 9 Modified Conflict Tactic Scale for significant abuse over 24 months in intervention and control groups.
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TABLE 13 Carers’ use of health and social care services at 12 and 24 months
Services
12 months 24 months
TAU (N= 67), % (n)
using service
Intervention
(N= 138), % (n)
using service
TAU (N= 64), % (n)
using service
Intervention
(N= 132), % (n)
using service
Outpatient services
Outpatient hospital services 24.7 (19) 32.7 (50) 27.6 (24) 32.9 (53)
Community-based services
Admiral Nurse 3.9 (3) 3.3 (5) 1.3 (1) 1.9 (3)
Chiropodist 6.5 (5) 11.1 (17) 6.5 (5) 8.5 (13)
Counsellor 3.9 (3) 3.3 (5) 2.6 (2) 1.9 (3)
Dentist 28.6 (22) 27.0 (40) 23.4 (18) 31.3 (48)
GP 42.9 (33) 35.2 (53) 48.1 (37) 44.4 (68)
Optician 10.4 (8) 8.5 (13) 16.4 (25) 16.4 (25)
Outreach worker 1.3 (1) 0.0 (0) 0.0 (0) 0.0 (0)
Home care worker/care attendant 0.0 (0) 0.7 (1) 3.9 (6) 0.0 (0)
Physiotherapist 1.3 (1) 2.1 (3) 1.4 (2) 1.4 (2)
District nurse 2.6 (2) 0.7 (1) 0.7 (1) 0.7 (1)
Support worker 0.0 (0) 0.7 (1) 0.7 (1) 0.7 (1)
Psychotherapist 0.0 (0) 0.7 (1) 0.0 (0) 0.7 (1)
Occupational therapist 0.0 (0) 0.7 (1) 0.7 (1) 0.7 (1)
Speech and language therapist 0.0 (0) 0.0 (0) 0.0 (0) 0.7 (1)
Practice nurse 1.3 (1) 0.7 (1) 0.0 (0) 3.9 (6)
Cardiac nurse 0.0 (0) 0.0 (0) 0.0 (0) 0.7 (1)
Ambulance transport 0.0 (0) 0.0 (0) 0.0 (0) 0.7 (1)
Social worker 0.0 (0) 0.0 (0) 0.0 (0) 0.7 (1)
Other services 2.6 (2) 0.7 (1) 0.0 (0) 2.7 (3)
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Cost-effectiveness ratio
Results from the net benefit regression using the two outcomes examined in the economic evaluation
(QALYs and HADS-T score) over 1–24 months are summarised and the ICERs reported in Table 15. Similar
to the analyses conducted over the 8-month time period, the costs and outcome differences are obtained
after adjustment for baseline characteristics and are influenced by the sample with complete data for
each outcome.
Over the 24 months, carers who received the START intervention had slightly, but not statistically
significantly, higher total costs and better, although not statistically significant, differences in outcomes
whether measured in terms of health-related QoL (QALY) or affective symptoms (HADS-T). We explored
the decision-maker’s willingness to pay for gains in QoL and affective symptoms to assess whether or not
TABLE 14 Health and social care service costs and outcomes at 12 and 24 months for carers in the intervention and
TAU groups and differences between START and TAU groups
Cost categories and
outcomes used in the
economic evaluationa
TAU, mean (SD) Intervention, mean (SD) Intervention vs. TAU over
1–24 months, difference
(95% CI) adjusted for
baseline variables
9–12
months
21–24
months
9–12
months
21–24
months
Costs (£, 2009–10)a
Outpatient 88 (190) 102 (289) 90 (154) 111 (213) 26 (–117 to 170; n= 176)
Community 143 (336) 94 (170) 132 (329) 108 (144) –44 (–172 to 84; n= 176)
Other 5 (31) 0 (0) 2 (19) 67 (699) 67 (–162 to 296; n= 176)
Total 236 (390) 196 (332) 224 (373) 286 (765) 173 (–115 to 460; n= 175)
Outcomes used in the economic evaluationb
EQ-5D 0.81 (0.19) 0.75 (0.18) 0.79 (0.23) 0.72 (0.24) 0.05 (–0.03 to 0.13; n= 184)
HADS-T scoresa 14.6 (8.9) 14.4 (8.9) 12.5 (7.9) 12.7 (7.7) –2.45 (–4.01 to –0.90; n= 200)
a Direct cost of intervention not included.
b Discounted rate= 3.5%; formula 1/(1+ r)n; r= discount rate, n= years into the future.
TABLE 15 Treatment and cost effects (with 95% CI) and ICERs over 24 months
Measure
Incremental differences (START minus
TAU) and ICERs 24-month evaluation
time point
With QALY as outcome (n= 144)a
Incremental health and social care costs (£, 2009–10), mean (95% CI) £336 (–£223 to £895)
Incremental QALY gain, mean (95% CI) 0.03 (–0.01 to 0.06)
ICER (£ per QALY) £11,200
With HADS-T as outcome (n= 156)b
Incremental health and social care costs (£, 2009–10), mean (95% CI) £303 (–£206 to £812)
Incremental HADS-T score change (reversed so higher scores show better
outcomes), mean (95% CI)
1.52 (–0.57 to 3.62)
ICER (£ per unit change on HADS-T) £199
a Sample size based on complete data for QALYs and cost measures.
b Sample size based on complete data for HADS-T and cost measures.
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these results imply that the START intervention is cost-effective. We computed the ICERs and plotted the
associated CEACs, and examined the CIs around NMB.
Looking at QALY as the outcome, the mean cost per QALY gain was £11,200. The CEAC is shown in
Figure 10. At the £20,000 per QALY threshold associated with NICE recommendations, the probability that
the START intervention would be seen as cost-effective was 65%, and at the higher NICE threshold of
£30,000 it was 75%.
For the other outcome measure, the HADS-T measure of affective symptoms, mean cost per 1-point
difference on the HADS-T was £199. The CEAC threshold for this outcome measure is shown in Figure 11.
Assuming a willingness to pay of £500, the probability that the START intervention would be seen as
cost-effective would be 78%.
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FIGURE 10 Cost-effectiveness acceptability curve: START intervention (manual-based coping strategy therapy)
vs. TAU; health and social care perspective, with effectiveness measured in QALY gain over 24 months.
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FIGURE 11 Cost-effectiveness acceptability curve: START intervention (manual-based coping strategy therapy)
vs. TAU; health and social care perspective, with effectiveness measured in HADS gain over 24 months.
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The discounted incremental costs and outcomes at 24 months, at rates of 0% and 6%, are shown in
Appendix 1. Discounting the incremental cost and outcomes by 0% and 6% did not greatly alter
the findings.
Sensitivity analysis
We followed the same approach as in the 8-month analysis to assess the robustness of the findings of
the cost-effectiveness analysis at 24 months. In the first sensitivity analysis, we adjusted for significant
differences on demographic and clinical predictors of missing values. This analysis did not alter the results
and is summarised in Table 16. The mean ICER values from this analysis are £9767 per additional QALY
and £125 per 1-point difference in HADS-T score.
Figure 12 shows the CEAC with QALY as the measure of outcome. The START intervention has an
approximately 67% likelihood of being seen as cost-effective at the lower bound of NICE threshold of
£20,000, rising to 75% at the £30,000 threshold.
Figure 13 shows the CEAC with HADS-T score as the measure of outcome. The START intervention has an
approximately 89% likelihood of being seen as cost-effective at £500. The likelihood of cost-effectiveness
is above 95% if the willingness to pay for a 1-point improvement in outcome is > £1000.
In the second sensitivity analysis adjusted for imbalances in baseline characteristics, the findings were
similar to those from the primary analyses. The results are shown alongside those of the first sensitivity
analysis in Table 16. The mean ICER values from this second sensitivity analysis are £8567 per additional
QALY and £209 per 1-point difference in HADS-T score.
TABLE 16 Sensitivity analyses: treatment and cost effects (with 95% CIs) and ICERs over 24 months
Measure
Incremental differences (START minus TAU) and ICERs
over 24-month evaluation time period
Adjusting for significant
demographic and clinical
predictors of missing values
Adjusting for
baseline imbalances
With QALY as outcome (n= 144)a
Incremental health and social care costs (£, 2009–10),
mean (95% CI)
£293 (–£277 to £862) £257 (–£333 to £847)
Incremental QALY gain, mean (95% CI) 0.03 (–0.01 to 0.06) 0.03 (–0.01 to 0.06)
ICER (£ per QALY) £9767 £8567
With HADS-T as outcome (n= 156)b
Incremental health and social care costs (£, 2009–10),
mean (95% CI)
£252 (–£294 to 799) £282 (–£265 to £828)
Incremental HADS-T score change, mean (95% CI) 2.02 (–0.06 to 4.08) 1.35 (–0.95 to 3.64)
ICER (£ per unit change on HADS-T) £125 £209
a Sample size based on complete data for QALYs and cost measures.
b Sample size based on complete data for HADS-T and cost measures.
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The CEAC with QALY as the outcome measure is shown in Figure 14. At a threshold of £20,000,
the START intervention has a likelihood of being seen as cost-effective of 70%, rising to 80% at the
£30,000 threshold.
Figure 15 shows the CEAC with HADS-T score as the measure of outcome. This second sensitivity analysis
adjusting for factors associated with imbalances in baseline characteristics slightly increased the likelihood
that the START intervention would be seen as cost-effective. In this sensitivity analysis, the START
intervention has an approximately 72% likelihood of being seen as cost-effective at £500 and remained
above 82% if the willingness to pay for a 1-point improvement in outcome is over £1000.
The CIs around NMB for these two sensitivity analyses are shown in Appendix 2.
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FIGURE 12 Cost-effectiveness acceptability curve for START with QALY as the outcome measure over 24 months.
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FIGURE 13 Cost-effectiveness acceptability curve for START with HADS-T as the outcome measure over 24 months.
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FIGURE 14 Sensitivity analysis of CEAC with QALY as the outcome measure over 24 months.
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FIGURE 15 Sensitivity analysis of CEAC with HADS-T as the outcome measure over 24 months.
DOI: 10.3310/hta18610 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 61
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Livingston et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
47

Chapter 6 Discussion
Key findings
Primary and secondary outcome of clinical effectiveness
This study was a pragmatic RCT of a multicomponent intervention. It is the first study to show that
family carers of people with dementia referred to secondary or tertiary care benefit from a structured
psychological intervention delivered by psychology graduates and supervised by a clinical psychologist.
This change was significant in terms of both depression and anxiety symptoms and also in QoL and
depression caseness. The intervention was effective 8 months after randomisation and continued to work
2 years later. Abusive behaviour reduced in both groups and there was no significant difference between
them. There was an indication of possible reduction in the chances of being admitted to a care home but
this was not significant.
Primary and secondary outcome of cost-effectiveness
We examined whether or not eight sessions of manual-based coping strategy therapy delivered over
8–14 weeks by supervised psychology graduates to family carers of people with dementia added to TAU
was cost-effective compared with TAU alone. Over the 8-month evaluation period, the START intervention
was found to have a high probability of being seen as cost-effective by reference to both primary outcome
measures examined, i.e. improvements in carers’ affective symptoms and gains in carers’ health-related
QoL. The sensitivity analyses considering alternative approaches to the analysis suggest a more cautious
conclusion as to the cost-effectiveness of the START intervention.
Interpretation
The effect size in terms of the total mean affective symptoms was small, but previous evidence from
studies in which researchers set out to calculate what a clinically important difference in the HADS would
be suggests that treatment effects are in the range that is important to patients.54 This study, based on
consideration of an emotional function and mastery domain from a scale administered at the same times
as the HADS, found the minimally important difference in the HADS-T score to be 1.61 and 1.68 for the
former and latter domain, respectively.
Incidence of clinical depression increased in the control group but not in the intervention group, and the
ORs indicate that, at follow-up at 8 months, those in the TAU group were four times more likely, and at
24 months were five times more likely, to have clinically significant depression, suggesting that the
intervention is clinically important. In keeping with this, carer QoL improved.
We thought that in the long term this intervention may also delay care home admission of the person with
dementia and, therefore, increase his or her QoL. The short-term follow-up over 8 months did not show
this but at 2 years there was an indication that it may tend to delay care home admission and we will
reconsider this effect over the following 5 years. Previous studies of information and advice to people
with dementia and their families have suggested this can improve the patient’s QoL but not the carer’s
psychological symptoms and an intervention which is targeted at the carer may not help the person with
dementia to the same extent.55
This may be the explanation for the lack of effect on care recipients’ QoL. However, QoL is a complex
phenomenon and the measure we used is a global one, thus considering finance, housing and physical
health in addition to well-being, and this may have made it less likely to change.
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The cost-effectiveness finding is driven more by the outcome differences between the groups than by the
cost difference; for example, at the 8-month time point, carers in the control group were four times more
likely to have clinically significant depression than carers receiving the START intervention.
Our study was effective over time and acceptable to most participants, who made time and space for it
despite the commitments of being a carer and, frequently, also being employed or being unwell
themselves. There is little evidence of harm with withdrawal from the treatment being at a similar rate to
withdrawal from TAU arm, although one carer said that he found the therapy too upsetting and three felt
that it was not for them.
There are currently no interventions which have been shown to reduce elder abuse.56,57 Our study was not
powered to find a significant change in abuse and for ethical reasons we made clinicians aware of clinically
significant abusive behaviour in the control group; thus, abused carers in this group were often offered
clinical and social support as well as monitoring of the behaviour and, if felt appropriate, adult protection
measures were taken. Thus, we think it is unlikely that there would be a significant difference between
groups. We were pleased that abusive behaviour went down over time in both groups and previous
research has not suggested that this is what would happen without intervention.58 We do not know
whether those people who acted in an abusive way were more likely to refuse to participate in the study
(although the high rates of abusive behaviour even in relation to prevalence studies make this less likely)59
or to leave the study or if the care recipient was more likely to be admitted to a care home.
Strengths and limitations
Study design
This was designed as a pragmatic study with broad inclusion criteria and followed closely the Medical
Research Council guidance on the evaluation of a complex intervention. The clustering of therapists was
accounted for by the analysis, and outcome measures were carefully considered for validity and to ensure
the participants were not overburdened and an economic evaluation was conducted. The follow-up
rates were satisfactory at > 80% and sensitivity analyses adjusting for missing outcome data showed
similar results.
Sensitivity analyses
One of the strengths of the study is the sensitivity analyses, which showed the same results as for the
primary analysis.
Bias
We took care to minimise bias in several ways. We used standardised measures validated for the
population. Although randomisation was independent and follow-up raters were blinded to allocation to
avoid bias in allocation or in rater assessment, the family carers inevitably knew which group they were in.
Similarly, although the data were entered and cleaned while blind to intervention status, the statistical
team were aware that the intervention group was the larger group.
Health economics
Each carer recruited to the study was scheduled to have eight sessions with the therapist but some carers
had fewer sessions. Although this was taken into account in calculating the costs of the intervention,
the impact that different numbers of sessions might have had on carers’ outcomes was not the focus of
this study.
The evaluation was conducted from a health and social care perspective, and concentrated on outcomes
experienced by carers. We did not, therefore, measure the costs of treatment and care services used by the
individuals with dementia who were being supported by these carers, nor did we attach monetary values
to the time spent by carers in providing support to their relatives.
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Sample size for the study design was calculated on the basis of the power required to demonstrate
differences in one of the effectiveness measures and not on the basis of costs or cost-effectiveness.
Although it would have been preferable for the study also to have been powered on an economic variable,
this would have required a considerable increase in sample size given that economic measures tend to be
highly skewed. In turn this would have had implications for both the research budget and ethics, as it
would have been necessary to recruit participants beyond the point at which clinical dominance has been
determined. We used CEACs to represents the uncertainty in the estimation of the ICER.
Generalisability
We recruited a sample of carers with varying demographic and clinical characteristics from a range of
services. People were only excluded if they had dementia or lived too far away for the therapy to be
delivered. Further evidence of external validity is the demographic similarity between those who consented
and those who did not. Participants were recruited from three mental health trusts and from a neurology
centre for rare dementias and were from urban, suburban and rural areas. The trust differed in
geographical location (Essex and London) and in referrers (psychiatrists, neurologists, Admiral Nurses
and other mental health professionals).
Participants were in the main children (44%) or partners (42%) of the person with dementia but were
also in-laws, nieces and nephews, grandchildren, siblings and friends. The participants were of either
sex (31% male), throughout the adult age range (18–89 years) and from a range of ethnic (around
three-quarters white UK) and socioeconomic backgrounds. We had thought that those carers in paid work
might be unable to access the intervention, but this did not appear to be the case, and carers were
working full-time or part-time, or were retired or not currently working.
The carers’ scores on the outcome measures and burden at baseline ranged widely. Most of the people
with dementia had relatively mild dementia at baseline, with the mean clinical dementia scale rating being
1.5–1.6, with 1 meaning mild and 2 meaning moderate dementia. Thus, we think that the intervention is
generally acceptable to and the results are generally applicable to the family carers around the time people
present to secondary care with dementia in the UK. The levels of anxiety and depressive symptoms,
case-level anxiety and depression, neuropsychiatric symptoms and carer abusive behaviour, however,
were slightly higher than in a recent cohort study of newly referred people with dementia and so those
with more problems may have been more likely to consent to the study.9,60
We did, however, inform the clinical teams about abusive behaviour of the carers in the TAU group when
there was no intervention in place and, thus, may have improved the outcome for the TAU.
Implementation of a complex intervention
The intervention was manual based, standardised and supervised, and the high-fidelity ratings and lack of
clustering by therapist suggests that the intervention can be delivered consistently. However, our researchers
saw most people at their homes and were more flexible in timing than most non-emergency services within
the NHS, sometimes seeing people in the evening. The researchers saw 19 out of 173 participants in the
evenings or out of hours for their intervention sessions. There was a very satisfactory follow-up rate of
88.1% overall at 8 months with similar rates in both arms. At 2 years, the follow-up rate was still over 80%.
The instruments were validated and standardised. These results suggest that our findings are valid.
Adherence to the intervention
Over three-quarters of the participants fulfilled our definition of compliance to the intervention. We found
it difficult to deliver the therapy to people who did not speak English, although there were only four of
those carers in the study, three of whom were in the intervention group. In retrospect, we did not allow
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enough time and budget to translate the whole manual and deliver the therapy with translators. It is, thus,
difficult to determine the effect of using the manual through a translator. As translating the manual is a
one-off process, the cost should be less of an issue if our findings are implemented in the NHS.
We have not been able to consider how many sessions were necessary to effect change as those people
who did not finish the sessions were different from those who did, often stopping through their own
illness or that of a family member. In addition, most people did all the sessions, and so the numbers
are small.
Overall evidence
Earlier studies of similar interventions in the USA have shown results consistent with ours. The study from
which we derived START uses a similar intervention and it also alleviated depressive symptoms in carers,
but we judge that our intervention is more practical for many carers as we did not require them all to
come to a group at the same time.17 There is no other rigorous study of an intervention delivered by
psychology graduates without previous clinical training, a group who are relatively available and
inexpensive but with a background in understanding the concepts. Within the USA, a similar therapy to
ours delivered to individuals was found to be significantly cost-effective in completers compared with
controls in terms of freeing up caring time.21 We are not aware of any other interventions in this group for
which health economic evaluations have been undertaken and we discuss this below.
Not all psychosocial interventions in family carers of people with dementia are effective.15 Recent RCTs of
psychosocial interventions in Europe (UK, Denmark and Norway) using different models have been
ineffective in terms of carer psychological symptoms and QoL, thus showing that our findings were not
explained solely by the offer of a therapist to spend time and attention.24,61,62
The earliest study of the three used trained ex-carers in a voluntary sector befriending intervention and was
not taken up by many carers.24 This suggests that acceptability, as well as the theoretical background,
needs to be a major focus of any intervention. Danish Alzheimer’s Intervention Study (DAISY) was a
multifaceted intervention involving both the person with mild Alzheimer’s disease and the carer.61 The
intervention was individualised to the dyad, who were seen both individually and together by a nurse for
counselling, based on validating the participants and focusing on retained and positive attributes and skills.
It allowed patient and carer to tell their own life story and explain what mattered to them. Carers and those
cared for also attended separate courses over a period of 1 year to educate them about dementia. Like our
study, it did not improve the patient’s QoL. Unlike ours, it did not help the carer’s QoL. In contrast to the
former study, 72% of participants completed the intervention according to the study’s definition (attending
three or more of individual and educational sessions). This suggests that the content of the intervention, as
well as its acceptability in terms of take-up, is also important. The intervention contrasts with our study in
validating the carer’s and care recipient’s position. Ours was more focused on accepting difficulties,
changing the carer’s thoughts and behaviour, and the carer finding ways to look after themselves,
communicate their needs, increase pleasant events and find help. The most recent study was also aimed at
the carer and the person with dementia.62 It was delivered by trained and supervised nurses and
occupational therapists and families and comprised education about dementia in two half-day sessions, five
individual counselling sessions when the therapist worked with them using a problem-solving model, and
six group meetings of 2 hours each, concentrating on problem-solving and increasing pleasant events.
Again, while the pleasant events were similar to our model, the focus on problem-solving rather than
acceptance differed.
Our earlier studies have found that family carers tend to become more anxious and depressed over
time without intervention, and that this is associated with an increase in abusive behaviour, and thus
we included carers who were not depressed at presentation to services.63,64 The preventative effect that
was found highlights that these carers can benefit from early intervention. This contrasts with a
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study of cognitive–behavioural interventions in patients with hip fracture which was unsuccessful
in preventing depression.65
Comparison of short- and long-term effects
The START intervention was effective in the short and long term (2 years); there was no difference
between the clinical effects at either time period. There is a paucity of literature which considers how long
it takes for a psychological intervention to work and the period for which it continues to work. Previous
research in carers had shown that interventions continue to work for an average of 7–11 months.66
One previous intervention with spouse carers of people with dementia with flexible content which included
behavioural management of difficult behaviour, promoting communication among family members and
staff availability to help with emergent behaviours and problems, found there was no significant effect at
4 months, but there was an effect at 1 year which was sustained for 3 years after the intervention.67
We thought that it was possible either that the effect of the intervention might wear off over time as
carers resorted to earlier coping strategies or that carers might continue to change their coping strategies
and the difference between groups would increase over time. Neither of these seemed to be the case
(at least alone) and there is no evidence of a ‘top-up’ being necessary to maintain the effect.
Structured psychological treatment of depression in other groups
A recent structured intervention in family carers of people with stroke with care competencies taught and
assessed by nurses did not improve their mood, QoL or burden, or improve patient outcome.15 This is
further evidence that knowledge by itself is not efficacious.
Previous work has found that a RCT of telephone-administered psychotherapy for depressive symptoms
worked over the 16 weeks it was administered, but was no longer significantly efficacious at 1 year.68
Similarly, a RCT of a ‘coping with depression’ psychoeducational group programme, with booster session
up to 4 months after the intervention had finished, was effective in reducing depression at 6 months but
not at 12 months.69
In contrast, a RCT of CBT as an adjuvant therapy for treatment-resistant depression found that it was
effective at the 6- and 12-month follow-up.70 Ten therapist-delivered sessions of CBT over the internet
were effective in reducing depression at 4 and 8 months (equivalent to our short-term measures).71
CBT treatment for health anxiety was effective at 6 months, 1 and 2 years with no significant increase
in costs for anxiety and depression, but was ineffective in increasing health-related QoL.72
We are unsure what the difference is between the therapies that continue to be efficacious for affective
symptoms and those that do not, but our intervention adds to the evidence that therapies can continue to
be effective over years.
Comparison with other health economics studies
There is little previous evidence on the cost-effectiveness of psychosocial interventions for carers of people
with dementia. A recent review found some evidence that such interventions could lead to greater
improvements in outcome and also generate cost savings.20 However, only one of the studies covered
by that review employed a similar therapeutic approach to the START intervention.21 It examined the
cost-effectiveness of a modular multicomponent intervention delivered in carers’ homes, with three
sessions by telephone, supplemented by five group sessions (five or six carers in each) delivered by
telephone. Focusing on hours of care-giving, the authors found a significant difference over the 6-month
study period, with carers in the intervention group having more time to dedicate to activities unrelated to
caregiving, which has potentially positive impacts on emotional well-being and QoL.
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Chapter 7 Conclusions
Implications for clinical practice
The START intervention is clinically effective in terms of carer impacts in the short term (8 months) and
long term (2 years) both for mood and for QoL.
Many countries, including the UK, face rapidly growing numbers of single people over the coming
decades, while policy frameworks continue to assume that families will remain the frontline providers of
(unpaid) care and support. Most people with dementia also prefer to receive support from family
members. In these circumstances, an intervention that is cost neutral, even over a relatively short period,
and which significantly improves carer mental health and QoL, should be made more widely available.
From these results, it would appear that the intervention is also likely to be perceived as cost-effective by
reference to NICE thresholds; there is, therefore, both a clinical and an economic case for supporting
carers of people with dementia using such an approach. This cost-effectiveness advantage arises because
the intervention improved carer outcomes while not significantly increasing overall costs, with the
additional cost of the intervention being partly counterbalanced by a reduction in service-related costs.
Our group has developed training and the manual is available online with the British Medical Journal
papers from this study and so it would be possible to disseminate this further to other memory services to
offer START as part of the routine management of dementia. In Camden and Islington, Memory Services
and Improving Access to Psychological Therapies services are piloting it.73 Further follow-up will consider
longer-term effects on carer mood, QoL, abusive behaviour and cost-effectiveness, and whether or not,
as in other longer-term studies, patient’s time to care home admission has been lengthened.74
Unanswered questions and future research
This study reports carer outcomes and that there was no evidence of a change in the magnitude of
effectiveness between 4 and 8 months, or at 12 months and 2 years, thus suggesting some lasting effect.
We have no data after 2 years. However, what we have is more than in many antidepressant trials, and
further analysis of the effectiveness of the intervention compared with antidepressants and the calculation,
if possible, of standardised effect size would help to put it in context.
One previous study found therapy led to improvement in spouse carer mental health over many years and
a reduction in nursing home admissions for patients.74 Patients whose spouses received the intervention
experienced a 28.3% reduction in the rate of nursing home placement compared with usual care controls,
with a difference in model-predicted median time to placement of 557 days. Improvements in carers’
satisfaction with social support, response to patient behaviour problems and symptoms of depression
collectively accounted for 61.2% of the intervention’s beneficial impact on placement. We do not yet
know whether or not our short therapeutic intervention will lead to a long-term reduction in carer nursing
home placement but are extending this study to find out. It may be that the inclusion of non-carers
(and, therefore, more often non-resident carers) means these outcomes differ.
Further qualitative research is needed to consider whether or not all of the intervention components were
valued by family carers, whether or not it was delivered at the appropriate time and how it could be
improved; we have now done this and our findings suggest that different carers use different components
and that a multimodel intervention is therefore appropriate.75 Future analysis should consider mechanism
of action, in terms of both coping strategies and freeing up carer time.
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In addition, it is important to consider the effects on people with dementia in terms of clinical outcome
(cognition, neuropsychiatric symptoms) and on health and social care costs. A cost-effectiveness analysis
considering the costs for both carers and care recipients, and the clinical and QoL effectiveness for them
both would be very informative and may add to the policy implications. In addition, we wish to analyse the
effect on abuse further and in particular the interaction between abuse and care home admission as abuse
may lead to admission and this may prevent further abuse.
Finally, the purpose of research is implementation of clinically effective and cost-effective interventions in
clinical practice and we have successfully applied for an implementation grant from the Alzheimer’s
Society, which includes assessing the implementation.
CONCLUSIONS
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Appendix 1 Unit cost of services
TABLE 17 Unit costs of services
Service
Unit cost (£)
2009–10a Source
Anticoagulant service (per attendance) 18 Department of Health (2010)49
Physiotherapy (per attendance) 38 Department of Health (2010)49
Podiatry (per attendance) 43 Department of Health (2010)49
Electrocardiography (per attendance) 45 Department of Health (2010)49
Ophthalmology (per attendance) 73 Department of Health (2010)49
Ear nose and throat (per attendance) 85 Department of Health (2010)49
Other adult outpatient services (per attendance) 90 Department of Health (2010)49
Dermatology (per attendance) 93 Department of Health (2010)49
Diagnostic imaging – CT scan (brain)
(per attendance)
95 Department of Health (2010)49
Orthopaedics (per attendance) 99 Department of Health (2010)49
Urology (per attendance) 102 Department of Health (2010)49
Accident and emergency not-leading-to-admitted
(per attendance)
106 Department of Health (2010)49
Endocrinology (per attendance) 110 Department of Health (2010)49
General surgery (per attendance) 112 Department of Health (2010)49
Gynaecology (per attendance) 118 Department of Health (2010)49
Clinical oncology (per attendance) 126 Department of Health (2010)49
Medical gastroenterology (per attendance) 128 Department of Health (2010)49
Diabetic medicine (per attendance) 130 Department of Health (2010)49
Cardiology (per attendance) 134 Department of Health (2010)49
Rheumatology (per attendance) 138 Department of Health (2010)49
Respiratory medicine (per attendance) 148 Department of Health (2010)49
Haematology (per attendance) 152 Department of Health (2010)49
Nephrology (per attendance) 156 Department of Health (2010)49
Neurology (per attendance) 168 Department of Health (2010)49
Diagnostic imaging – MRI (per attendance) 175 Department of Health (2010)49
Acute adult inpatient care (per bed-day) 295 Curtis (2010)50
Elderly rehabilitation services (per bed-day) 296 Curtis (2010)50
Admiral Nurse (per hour) 31 Curtis (2010)50
Chiropodist (per hour) 22 Curtis (2010)50
Counsellor (per hour) 34 Curtis (2010)50
Dentist (per attendance)b 87 Curtis (2010)50
GP (per consultation) 28 Curtis (2010)50
continued
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TABLE 17 Unit costs of services (continued )
Service
Unit cost (£)
2009–10a Source
NHS direct (per hour) 3 Curtis (2010)50
Optician (per hour) 29 Curtis (2010)50
Outreach worker (per hour) 15 Curtis (2010)50
Home care worker/care attendant
(per weekday hour)
21 Curtis (2010)50
Physiotherapist (per hour) 22 Curtis (2010)50
Psychotherapist (per hour) 39 Curtis (2010)50
Hygienist (per hour) 174 Department of Health (2010)49
Company medical check-up (per session)c 175 Marie Stopes International; www.mariestopes.org.
uk/Womens_services/Well_Woman_screening/
Company_health_screening.aspx
Nurse (advanced) (per hour) 37 Curtis (2010)50
Occupational therapist (per hour) 39 Curtis (2010)50
Community psychiatrist (per hour) 22 Curtis (2010)50
Practice nurse (per hour) 26 Curtis (2010)50
District nurse (per hour) 31 Curtis (2010)50
Social worker (per hour) 40 Curtis (2010)50
Speech and language therapist (per hour) 22 Curtis (2010)50
Ambulance transport (per journey)d 40–246 Curtis (2010)50
Dietician (per hour) 22 Curtis (2010)50
Clinical support worker nursing (per hour) 15 Curtis (2010)50
Support group (per hour) 9 Curtis (2010)50
Community nurse (per hour) 31 Curtis (2010)50
Orthodontist (per hour) 174 Curtis (2010)50
Day care: NHS provision (per day) 66 Curtis (2010)50
Day care: local authority provision (per day) 43 Curtis (2010)50
Day care: voluntary provision (per day) 42 Curtis (2010)50
Alzheimer’s café (per hour)e 6 Curtis (2010)50
Dementia course (per hour)f 17 Dementia UK; http://dementiauk.org/what-we-do/
learning-partnerships-and-training/opencources-
2011/courses-by-huest-trainers
Alternative complementary therapies (per hour) 40 Professor Jennifer Beecham, PSSRU, London
School of Economics and Political Science, 2012,
personal communication
Yoga and pilates (per hour) 7 www.thetotalcareclinic.co.uk/yoga-pilates-classes-
southampton.htm
CT, computerised tomography; MRI, magnetic resonance imaging.
a 2008–9 prices uprated to 2009–10 prices using the Hospital and Community Health Services Pay and Prices Index.
b Attendance assumed to last 30 minutes.
c Session is 30 minutes in duration.
d £40 for transport to hospital; £246 for emergency transport.
e Weighted average of day care provision by NHS, local authority and voluntary provision per day divided by 8 hours.
f 1-day 6-hour course assumed.
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Discounted treatment and cost effects and incremental
cost-effectiveness ratios over 24 months
TABLE 18 Treatment and cost effects (with 95% CI) and ICERs
Outcome
Incremental differences and ICERs
24-month evaluation time point
(discounted 0%)
Incremental differences and ICERs
24-month evaluation time point
(discounted 6%)
With QALY as outcome (n= 144)a
Incremental health and social care
costs (£, 2009–10), mean (95% CI)
£353 (–£223 to £929) £325 (–£223 to £874)
Incremental QALY gain, mean
(95% CI)
0.03 (–0.01 to 0.06) 0.03 (–0.01 to 0.06)
ICER (£ per QALY) £11,767 £10,833
With HADS-T as outcome (n= 156)b
Incremental health and social care
costs (£, 2009–10), mean (95% CI)
£315 (–£210 to £840) £295 (–£204 to £794)
Incremental HADS-T change (reversed
so higher scores show better
outcomes), mean (95% CI)
1.63 (–0.61 to 3.88) 1.45 (–0.55 to 3.45)
ICER (£ per unit change on HADS-T) £193 £203
a Sample size based on complete data for QALYs and cost measures.
b Sample size based on complete data for HADS-T and cost measures.
Discount rate= 3.5%; formula 1/(1+r)n; r= discount rate, n= years into the future.
TABLE 19 Treatment and cost effects (with 95% CIs) and ICERs following sensitivity analysis adjusting for
significant predictors of missing values
Outcome
Incremental differences and ICERs
24-month evaluation time point
(discounted 0%)
Incremental differences and ICERs
24-month evaluation time point
(discounted 6%)
With QALY as outcome (n= 144)a
Incremental health and social care
costs (£, 2009–10), mean (95% CI)
£308 (–£277 to £893) £282 (–£277 to £842)
Incremental QALY gain, mean
(95% CI)
0.03 (–0.01 to 0.07) 0.03 (–0.01 to 0.06)
ICER (£ per QALY) £10,267 £9400
With HADS-T as outcome (n= 156)b
Incremental health and social care
costs (£, 2009–10), mean (95% CI)
£264 (–£298 to £825) £245 (–£292 to £782)
Incremental HADS-T change (reversed
so higher scores show better
outcomes), mean (95% CI)
2.15 (–0.06 to 4.38) 1.92 (–0.05 to 3.90)
ICER (£ per unit change on HADS-T) £123 £128
a Sample size based on complete data for QALYs and cost measures.
b Sample size based on complete data for HADS-T and cost measures.
Discount rate= 3.5%; formula 1/(1+ r)n; r= discount rate, n=years into the future.
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TABLE 20 Treatment and cost effects (with 95% CIs) and ICERs, following sensitivity analysis adjusting for
baseline imbalances
Outcome
Incremental differences and ICERs
24-month evaluation time point
(discounted 0%)
Incremental differences and ICERs
24-month evaluation time point
(discounted 6%)
With QALY as outcome (n= 144)a
Incremental health and social care
costs (£, 2009–10), mean (95% CI)
£271 (–£336 to £877) £248 (–£332 to £828)
Incremental QALY gain, mean
(95% CI)
0.03 (–0.01 to 0.06) 0.03 (–0.01 to 0.06)
ICER (£ per QALY) £9033 £8267
With HADS-T as outcome (n= 156)b
Incremental health and social care
costs (£, 2009–10), mean (95% CI)
£293 (–£269 to £855) £274 (–£262 to £810)
Incremental HADS-T change (reversed
so higher scores show better
outcomes), mean (95% CI)
1.44 (–1.01 to 3.90) 1.28 (–0.90 to 3.45)
ICER (£ per unit change on HADS-T) £203 £214
a Sample size based on complete data for QALYs and cost measures.
b Sample size based on complete data for HADS-T and cost measures.
Discount rate= 3.5%; formula 1/(1+ r)n; r= discount rate, n= years into the future.
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Appendix 2 Net monetary benefit graphs
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FIGURE 16 Net monetary benefit line (with 95% CI lines): START intervention vs. TAU health and social care
perspective, with effectiveness measured in QALY gain over 8 months.
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FIGURE 17 Net monetary benefit line (with 95% CI lines): START intervention vs. TAU; health and social care
perspective, with effectiveness measured on HADS-T score over 8 months.
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FIGURE 18 Net monetary benefit line (with 95% CI lines): START intervention vs. TAU; health and social care
perspective, with effectiveness measured in QALY gain over 8 months following sensitivity analysis adjusting for
significant predictors of missing values.
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FIGURE 19 Net monetary benefit line (with 95% CI lines): START intervention vs. TAU; health and social care
perspective, with effectiveness measured in QALY gain over 8 months following sensitivity analysis adjusting for
baseline imbalances.
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FIGURE 20 Net monetary benefit line (with 95% CI lines): START intervention vs. TAU; health and social care
perspective, with effectiveness measured in QALY gain over 24 months.
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FIGURE 21 Net monetary benefit line (with 95% CI lines): START intervention vs. TAU; health and social care
perspective, with effectiveness measured on HADS-T score over 24 months.
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FIGURE 22 Net monetary benefit line (with 95% CI lines): START intervention vs. TAU; health and social care
perspective, with effectiveness measured in QALY gain over 24 months following sensitivity analysis adjusting for
significant predictors of missing values.
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FIGURE 23 Net monetary benefit line (with 95% CI lines): START intervention vs. TAU; health and social care
perspective, with effectiveness measured in QALY gain over 24 months following sensitivity analysis adjusting for
baseline imbalances.
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